Archive for the ‘Crispr’ Category

Much has changed about testing for current COVID-19 infection and antibody testing for past exposure. Heres an updated guide on what you need to know:

What we have now: The most widespread tests to diagnose current COVID-19 infection are the polymerase chain reaction or PCR tests that involve swabbing a persons nasal passages and looking for the coronavirus genetic material.

Results come as quickly as less than 15 minutes with the rapid test, about which false results have been an issue, or within a couple of days if sent to a lab.

Whats coming: More tests are on the way. Scientists at Sherlock Biosciences in Cambridge, Massachussetts, are using gene-editing technology known as CRISPR to develop another type of rapid test that could be produced for as little as $6 per test.

And a new saliva test developed at Rutgers University holds great promise because it would be easy to administer even at home.

Anybody can spit, says Dr. Robert Murphy, executive director of the Institute for Global Health at Northwestern Universitys Feinberg School of Medicine, who is helping a national effort to develop point-of-care technologies. Saliva will open the door for mass testing.

What about antigen tests: Think rapid-strep tests. These still involve a swab like the PCR tests, but give quicker results and are cheaper and simpler to manufacture.

Antigen tests target substances given off by a virus that trigger antibodies in an infected person.

These drew widespread attention recently when Quidel Corp. of San Diego got federal approval for its rapid COVID-19 antigen test. But dont expect to be able to get one yet. Quidel has said its aiming to produce 1.8 million of the tests a week by this summer.

The antigen tests will be relatively easy to manufacture and use. But they produce a higher number of false-negative results.

Still, they could be useful if combined with PCR tests or used in a testing program in which people say, at a nursing home or factory get retested often.

How they work: We now know these as antibody tests. They involve a blood test yes, stick out your arm, and make a fist but a briefer one than you might be used to.

They test a small amount of blood for the presence of antibodies produced by the bodys immune system.

With COVID-19, these antibodies usually appear 14 to 21 days after infection. So these tests are done after the fact, as confirmation.

What they might reveal: Beyond that, theres hope that having the antibodies might protect against future infections.

One problem: Many of the antibody tests that were rushed out, with no vetting by the government, in response to the pandemic arent very accurate.

Also, scientists dont know how long antibodies stay in a recovered persons system or how well they might protect us. Antibodies to the onetime scourge of measles, for instance, protect a person forever. But antibodies to the common cold or influenza not so much because of the wide range of cold and flu viruses and those viruses ability to rapidly mutate.

Still, scientists are eager to launch widespread antibody testing to get a big-picture look at where the virus has hit within geographic areas and among certain populations.

For weeks, Chicago and the state of Illinois faced a shortage of test kits and swabs.

Now, weve reached the point where anyone who feels ill can and should be tested for COVID-19, says Dr. Emily Landon, executive medical director for infection prevention and control at University of Chicago Medicine: Were currently at a place where anyone who has symptoms can be tested.

The same is true if you suspect that youve been exposed, symptoms or not, Landon says.

Though some places are charging for these, many hospitals and clinics are offering no-fee tests.

For guidance, call your doctor or go online to Chicago.gov or Coronavirus.illinois.gov.

Go here to see the original:
Coronavirus testing: an updated guide on COVID-19 PCR, antibody, saliva and antigen tests - Chicago Sun-Times

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (Repare), a precision oncology company pioneering synthetic lethality to develop novel therapeutics that target specific vulnerabilities of tumors in genetically defined patient populations, today announced it has entered into an exclusive, worldwide research collaboration with Bristol Myers Squibb (BMS) (NYSE:BMY).

This collaboration will help to ensure that our novel discoveries are being broadly prosecuted in the search for the next generation of precision oncology medicines, said Lloyd M. Segal, President and Chief Executive Officer of Repare Therapeutics. Bristol Myers Squibb brings key strategic capabilities to this partnership and the resources to maximize our platforms potential while allowing us to independently focus on our proprietary clinical and near-clinical programs.

We look forward to collaborating with Repare and to applying their SNIPRx technology to enable the identification of novel precision oncology therapeutics, said Rupert Vessey, M.A., B.M., B.Ch., F.R.C.P., D.Phil., Executive Vice President, Research & Early Development, Bristol Myers Squibb. Repares distinctive team and technology have the potential to lead to the discovery of important targeted drug candidates that can result in new precision therapies for patients.

Under the terms of the agreement, the companies will leverage Repares proprietary, CRISPR-enabled genome-wide synthetic lethal target discovery platform, SNIPRx, to jointly identify multiple synthetic lethal precision oncology targets for drug candidates. Repare will grant BMS exclusive worldwide rights to develop and commercialize therapeutics for select validated synthetic lethal precision oncology targets discovered under the collaboration.

As part of the agreement, BMS will make an upfront payment of $65 million which includes a $15 million equity investment in Repare. Repare will be eligible to receive up to approximately $3 billion in license fees, discovery, development, regulatory and sales-based milestones, in addition to royalty payments on net sales of each product commercialized by BMS.

About Repares SNIPRx Platform

Repare Therapeutics SNIPRx platform is a genome-wide CRISPR-based screening approach that utilizes proprietary isogenic cell lines to identify novel and known synthetic lethal gene pairs and the corresponding patients who are most likely to benefit from the Companys therapies based on the genetic profile of their tumors. Repares platform enables the development of precision therapeutics in patients whose tumors contain one or more genomic alterations identified by SNIPRx screening, in order to selectively target those patients most likely to achieve clinical benefit from resulting product candidates.

About Repare Therapeutics, Inc.

Repare Therapeutics is a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Companys pipeline includes its lead product candidate RP-3500, a potential leading ATR inhibitor, as well as CCNE1-SL inhibitor and Pol inhibitor programs. For more information, please visit http://www.reparerx.com.

SNIPRx is a registered trademark of Repare Therapeutics Inc.

Read the original post:
Repare Therapeutics Announces Multi-Target Discovery Collaboration with Bristol Myers Squibb - Business Wire

Global Clustered Regularly Interspaced Short Palindromic Repeats Market was valued US$ 711.24 Mn in 2018 and is expected to reach US$ XX Mn by 2026, at a CAGR of XX% during a forecast period.

REQUEST FOR FREE SAMPLE REPORT: https://www.maximizemarketresearch.com/request-sample/21900/

The key driving factors of the global clustered regularly interspaced short palindromic repeats market are increasing demand for drug discovery, a risk of congenital anomalies, late pregnancies leading to birth disorders, increasing size of the geriatric population, and investment in path-breaking research technology. Lack of awareness and probable misappropriated use of the CRISPR gene editing tool are the major factors limiting the CRISPR market growth.

The global clustered regularly interspaced short palindromic repeats market is segmented into the products, application, end-uses, and region. In terms of products, the global clustered regularly interspaced short palindromic repeats market is classified into design tools, plasmids, vectors, library, control kits, proteins, genomic RNA, and other products.

Based on the application, the global clustered regularly interspaced short palindromic repeats market is divided into genome editing & genetic engineering, GRNA database & gene library, CRISPR plasmid, human stem cells, and cell line engineering. By application, genome editing & genetic engineering is used for modifying an organisms genome, where deletions, insertions or replacements are carried out in the DNA of the living organism by making use of molecular machinery and engineered nucleases.

In terms of end-uses, global clustered regularly interspaced short palindromic repeats market is segmented into industrial biotech biological research, agricultural research, and therapeutics and drug discovery. changing lifestyles, late pregnancies leading to birth disorders, increasing demand for drug discovery, synthetic genes leading the way, investment in path-breaking research technology and aging genetic disorders are drive the growth of biological research segment.

Based on regions, the global clustered regularly interspaced short palindromic repeats market is divided into five main regions are America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Geographically, Asia-Pacific market is anticipated to be the fastest-growing region in the global CRISPR market due to the large population of Japan and China is suffering from diabetes and other peripheral diseases, and the prevalence of these diseases growing at a very reckless rate.

Key players operating in global clustered regularly interspaced short palindromic repeats market are Addgene, CRISPR Therapeutics, Editas Medicine, Egenesis, Inc., GE Healthcare, GenScript Biotech Corporation, Horizon Discovery Group PLC, Integrated DNA Technologies, Inc., Intellia Therapeutics, Inc., and Lonza Group.

DO INQUIRY BEFORE PURCHASING REPORT HERE: https://www.maximizemarketresearch.com/inquiry-before-buying/21900/

The objective of the report is to present comprehensive analysis of Global Clustered Regularly Interspaced Short Palindromic Repeats Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding Global Clustered Regularly Interspaced Short Palindromic Repeats Market dynamics, structure by analyzing the market segments, and project the Global Clustered Regularly Interspaced Short Palindromic Repeats Market size. Clear representation of competitive analysis of key players by Global Clustered Regularly Interspaced Short Palindromic Repeats Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Clustered Regularly Interspaced Short Palindromic Repeats Market make the report investors guide.The Scope of the Global Clustered Regularly Interspaced Short Palindromic Repeats Market:

Global clustered regularly interspaced short palindromic repeats market, by products:

Design tools Plasmids Vectors Library Control kits Proteins Genomic RNA Other productsGlobal Clustered Regularly Interspaced Short Palindromic Repeats Market, By Application:

Genome editing & genetic engineering GRNA database & gene library CRISPR plasmid Human stem cells Cell line engineeringGlobal Clustered Regularly Interspaced Short Palindromic Repeats Market, By End-Uses:

Industrial biotech Biological research Agricultural research Therapeutics and drug discoveryGlobal Clustered Regularly Interspaced Short Palindromic Repeats Market, By Region:

North America Europe Middle East & Africa Asia Pacific Latin AmericaKey Players Operating In Global Clustered Regularly Interspaced Short Palindromic Repeats Market:

Addgene CRISPR Therapeutics Editas Medicine Egenesis, Inc. GE Healthcare GenScript Biotech Corporation Horizon Discovery Group PLC Integrated DNA Technologies, Inc. Intellia Therapeutics, Inc. Lonza Group

MAJOR TOC OF THE REPORT

Chapter One: Clustered Regularly Interspaced Short Palindromic Repeat Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Clustered Regularly Interspaced Short Palindromic Repeat Market Competition, by Players

Chapter Four: Global Clustered Regularly Interspaced Short Palindromic Repeat Market Size by Regions

Chapter Five: North America Clustered Regularly Interspaced Short Palindromic Repeat Revenue by Countries

Chapter Six: Europe Clustered Regularly Interspaced Short Palindromic Repeat Revenue by Countries

Chapter Seven: Asia-Pacific Clustered Regularly Interspaced Short Palindromic Repeat Revenue by Countries

Chapter Eight: South America Clustered Regularly Interspaced Short Palindromic Repeat Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Clustered Regularly Interspaced Short Palindromic Repeat by Countries

Chapter Ten: Global Clustered Regularly Interspaced Short Palindromic Repeat Market Segment by Type

Chapter Eleven: Global Clustered Regularly Interspaced Short Palindromic Repeat Market Segment by Application

Chapter Twelve: Global Clustered Regularly Interspaced Short Palindromic Repeat Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Clustered Regularly Interspaced Short Palindromic Repeat Market Report at: https://www.maximizemarketresearch.com/market-report/global-clustered-regularly-interspaced-short-palindromic-repeats-market/21900/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

Connect With us at LinkedIn LinkedIn

Connect with us at Facebook Facebook

Contact With Us at Twitter Twitter

Read the rest here:
Global Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Market : Industry Analysis and... - Azizsalon News

The Global Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology Market is known to provide a comprehensive and detailed information of the keyword Market for the estimated forecast period. In addition, the report also analyses the overall growth of the market in the estimated forecast period. It also covers and determines the market growth and market share for the estimated forecast period. Moreover, the report provides in depth and detailed analysis for the market in the estimated time frame. It also covers and analyze several segments which are present in the market. Furthermore, detailed analysis is done to determine the competitive landscape of the market share, market size, for the estimated forecast period. The report is also known to cover detailed and in depth analysis of the major trends which are covered for the Global Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology Market.

This study covers following key players:

Thermo Fisher ScientificMerckGenScriptIntegrated DNA TechnologiesHorizon Discovery GroupAgilent TechnologiesCellectaGeneCopoeiaNew England BiolabsOrigene TechnologiesSynthego CorporationToolgen

Request a sample of this report @https://www.orbisresearch.com/contacts/request-sample/4421337?utm_source=Birendra

The study is done with the help of analysis such as SWOT analysis and PESTEL analysis. SWOT analysis includes the study of Threats, weaknesses, strengths and opportunities that the Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology Market. This method of market analysis gives the idea about the competitors and helps a vendor to identify the factors that will make them different from others. Whereas PESTEL analysis is the study concerning Economic, Technological, legal political, social, environmental matters. External factors affecting the market are determined by PESTEL analysis. PESTEL analysis making strategies and planning for all the types of business that may be opening a new company in a new location or an expansion of a product line.

There are different marketing strategies that every marketer looks up to in order to ace the competition in the Global market. Some of the primary marketing strategies that is needed for every business to be successful arePassion, Focus, Watching the Data, Communicating the value To Your Customers, Your Understanding of Your Target Market. There isa target set in market that every marketing strategy has to reach. The key players of Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology industry, their product portfolio, market share, industry profiles are studied in this report.

Access Complete Report @https://www.orbisresearch.com/reports/index/global-clustered-regularly-interspaced-short-palindromic-repeats-crispr-technology-market-size-status-and-forecast-2020-2026?utm_source=Birendra

Market segment by Type, the product can be split into

ProductsServices

Market segment by Application, split into

Biomedical ApplicationsAgricultural ApplicationsIndustrial ApplicationsBiological Research

The major market players are studied on the basis of gross margin, production volume, price structure, and market value. Adaptation of new ideas and accepting the latest trends are some the reasons for any markets growth. The Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology Market has its impact all over the globe. On global level Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology industry is segmented on the basis of product type, applications, and regions. It also focusses on market dynamics, Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology growth drivers, developing market segments and the market growth curve is offered based on past, present and future market data. The industry plans, news, and policies are presented at a global and regional level.

For Enquiry before buying report @https://www.orbisresearch.com/contacts/enquiry-before-buying/4421337?utm_source=Birendra

About Us:Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155

The rest is here:
GLOBAL CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS (CRISPR) TECHNOLOGY MARKET 2020: SIZE, SHARE, GROWTH ANALYSIS, PRESENT STATUS,...

ZUG, Switzerland and CAMBRIDGE, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate virtually in the following investor conferences in June:

Jefferies Global Healthcare ConferenceDate:Tuesday, June 2, 2020Fireside chat: 1:30 p.m. ET

Goldman Sachs 41st Annual Global Healthcare ConferenceDate:Tuesday, June 9, 2020Fireside chat: 9:40 a.m. ET

A live webcast of these events will be available on the "Events & Presentations" page in the Investors section of the Company's website athttps://crisprtx.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.

About CRISPR TherapeuticsCRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit http://www.crisprtx.com.

Investor Contact:Susan Kim+1 617-307-7503susan.kim@crisprtx.com

Media Contact:Rachel EidesWCG on behalf of CRISPR+1 617-337-4167reides@wcgworld.com

Read more:
CRISPR Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire

By Piyush K. Jain6 minute Read

A desperately needed tool to curb the COVID-19 pandemic is an inexpensive home-based rapid testing kit that can detect the coronavirus without needing to go to the hospital.

The Food and Drug Administration has approved a few home sample collection kits but a number of researchers, including myself, are using the gene-editing technique known as CRISPR to make home tests. If they work, these tests could be very accurate and give people an answer in about an hour.

I am a biomolecular scientist with training in pharmaceutical sciences and biomedical engineering, and my lab focuses on developing next-generation of technologies for detecting and treating cancer, genetic, and infectious diseases.

The COVID-19 disease is caused by a coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Unlike humans which carry their genetic material encoded in DNA, the coronavirus encodes theirs in a related molecule called RNA.

My research group recently engineered a sensitive CRISPR-based technology, that we named CRISPR-ENHANCE, and used it to create a rapid test for SARS-CoV-2 RNA. Our assay works like a pregnancy test and shows two purple-colored lines if the sample is positive for the virus. Using our technology, I envision developing a test kit that would allow rapid detection of SARS-CoV-2 RNA in saliva within 45 to 60 minutes at home without needing any expensive equipment.

The FDA recently gave a green light to a couple of sample collection kits from LabCorp and Everywell under the Emergency Use Authorization (EUA) that would allow people to ship out the nasal swab samples for analysis. Patients can take a swab of their nose, ship the samples to a lab, and wait for a few days to get the results back.

Although not an at-home testing kit, the test allows the samples to be shipped directly to a lab for detecting SARS-CoV-2 RNA. There they use a technique called reverse transcription-polymerase chain reaction (RT-PCR), which converts the viral RNA into DNA so that it can be easily multiplied and detected.

Although most FDA-approved tests are based on detecting SARS-CoV-2 RNA at an early stage, before symptoms even appear, such tests can only be performed in a laboratory setting with expensive equipment and can take multiple days to get the results.

Several antibody testing kits have been approved by the FDA that use a paper-based lateral flow strip, also similar to an at-home pregnancy testing strip, for detecting antibodies called IgM and IgG. Almost all SARS-CoV-2-infected patients make antibodies within 19 days of onset of symptoms and then the body continues to make detectable antibodies for several weeks to months even after symptoms fade away. Therefore, the Centers for Disease Control and Prevention recommends using antibody tests for detecting past infections.

However, the coronavirus is usually very active and contagious in the first week of infection and peaks on the day of onset of symptoms. Therefore, to prevent the spread of the coronavirus, it is extremely important to detect the coronavirus early to block the spread.

The antibody testing can be great for detecting past infections but they cannot reliably detect current or early infections. The delayed appearance and patient-to-patient variability of antibodies in a blood test further complicates the COVID-19 diagnosis with antibody testing kits.

In addition, the variability between different antibody testing methods has raised doubts about the reliability of these test kits.

Therefore, the National Institutes of Health recently announced a Rapid Acceleration of Diagnostics (RADx), which offers up to U.S.$500 million in funding for ramping up the technologies that detect the SARS-CoV-2 virus.

Most people know of CRISPR/Cas systems as a famous gene-editing technology that can precisely edit DNA. Researchers engineer a guide RNA molecule with a target genetic sequence that serves like a GPS and zooms in on a location on the DNA where a Cas protein, a pair of molecular scissors, can cut at the desired location.

Scientists in the labs of Feng Zhang at MIT, Jennifer Doudna at UC Berkeley, and others discovered several newer versions of CRISPR/Cas systems, including ones using the proteins Cas12a and Cas13a-d, which get crazy cutting once they find their match.

My colleagues and I have used this Cas12a-based CRISPR technique to detect the coronavirus.

The coronavirus RNA activates CRISPR/Cas, transforming a pair of controlled molecular scissors into an unstoppable chainsaw. When the the CRISPR/Cas enzyme activates, we know that the genetic sequence of the coronavirus is present in the saliva sample. To make the signal of the coronavirus stronger in the testing kit, we add millions of synthetic reporter molecules, which are also chopped up by the CRISPR/Cas mechanism. This means that within minutes we can detect detect the presence of coronavirus.

Under EAU, the FDA recently approved the first CRISPR-based SARS-CoV-2 RNA testing kit from Sherlock Biosciences for testing nasal swabs in a lab. Although not yet approved for at-home testing, this is a big leap toward the development of CRISPR-based diagnostics.

While similar CRISPR-based test kits are in development, including one from Mammoth Biosciences and others, our CRISPR-ENHANCE technology relies on engineered CRISPR RNAs that increases the speed of Cas12a chainsaw by between three- and fourfold.

This technique dramatically enhances the sensitivity of detection. Our system can detect fewer virus in a clinical sample faster with a clear visual readout. We are in the process of clinically validating the CRISPR-ENHANCE technology for SARS-CoV-2 RNA detection.

Standard collection method for detecting respiratory viruses in the clinic is the nasal swab. However, coronaviruses have been detected at comparable levels in saliva, so some researchers are now turning to saliva for diagnostic testing.

Collecting saliva is not only less invasive than the nasal swabs but also contains more virus, which makes it easier to detect with RT-PCR. In fact, an at-home saliva collection kit just received a green light by the FDA on May 8, 2020. In our validation study we will be internally comparing our test between the nasal swabs and saliva for FDA approval.

We are developing a six-step procedure for home-based testing for saliva along with the nasal swabs. Here is how it would work with saliva.

Spit into a sample collection tube that contains dry chemical reagents that will begin to react with your saliva when you drop the closed tube into the warm water for 30 minutes.

The heat helps the chemicals break up the virus particle and expose the viruss genetic materialRNA. The RT-PCR reagents basically multiply the viral RNA creating billions of copies, which are more easily detected.

After 30 minutes, transfer the contents of the collection tube to a second tube containing dried CRISPR components and leave it at room temperature for 10 to 15 minutes.

Only if CRISPR/Cas finds the specific coronavirus RNA will it become active and chop up the synthetic reporter molecules that are engineered and added to this second tube. This part happens in just six minutes.

We then drop a paper strip into the second tube. Within 30 seconds one or two purple bands reveal the results.

The health care provider can then direct the individual to either quarantine, isolate, and/or recommend further testing such as antibody-based tests. In our study, currently under peer review, we demonstrated that the ENHANCE technology itself is versatile and can also be adopted for detecting a range of targets including HIV, HCV, and prostate cancer.

While there are several labs and companies rushing to develop similar CRISPR-based coronavirus detection kits for saliva testing, we believe our approach offers the fastest detection. We hope to bring the cost of the kit down to between $1 and $2 so that developing countries can also afford a rapid and reliable coronavirus testing kit.

Piyush K. Jain is an assistant professor of chemical engineering at Herbert Wertheim College of Engineering, part of the UF Health Cancer Center at the University of Florida. This article is republished from The Conversation.

Original post:
Why CRISPR could be the key to faster at-home coronavirus tests - Fast Company

SAN DIEGO, May 26, 2020 /PRNewswire/ --ViaCyte, Inc., a privately held regenerative medicine company, today announced the close of an approximately $27 million private financing, part of the Series D preferred stock financing entered into in late 2018. Investors included, Bain Capital Life Sciences, TPG Capital, RA Capital Management, Sanderling Ventures, and several individual supporters of the Company. Proceeds from the financing will be used to further advance the Company's multi-product candidate approach to develop medicines that have the potential to transform the way insulin-requiring diabetes is managed, potentially providing a functional cure for patients with type 1 diabetes.

Coinciding with the financing, the Company also appointed Ian F. Smithas Executive Chairperson. Mr. Smith was appointed to the Company's Board of Directors in July 2019 and succeeds Fred Middleton, who remains on the board.

Commenting on the financing, Paul Laikind, Ph.D., Chief Executive Officer and President of ViaCyte, said, "During these difficult times we are grateful for the continued support of our investors as well as our clinical trial participants, whose safety and health remains our focus and commitment. We are steadfast in our mission to deliver potentially life sustaining therapies for patients with insulin-requiring diabetes and to continue the significant progress we have made in the past year. ViaCyte is the first company to demonstrate production of C-peptide, a biomarker for insulin, in patients with type 1 diabetes receiving a stem cell-derived islet replacement. Moving forward, we are optimizing the effectiveness of both PEC-Direct and PEC-Encap, the latter of which incorporates novel device material technology created in collaboration with W.L. Gore & Associates. We are also making important progress on our PEC-QT program with our partner, CRISPR Therapeutics, and are now moving into pre-IND activities. This program is designed to eliminate the need for immuno-suppression and could have a transformative impact on a broader population of insulin-dependent patients."

Dr. Laikind continued, "In conjunction with the closure of the financing, we are also pleased to announce the appointment of Ian F. Smith as our Executive Chairperson, succeeding Fred Middleton. Since joining the board last July, Ian and I have worked closely to accelerate ViaCyte's growth and prepare for the future. We are extremely grateful to Fred for his many years of service as Chairperson of ViaCyte's Board of Directors. Throughout his time leading the Board, Fred provided expert guidance as ViaCyte has consistently broken new ground in the field of regenerative medicine and cell replacement therapies."

Mr. Middleton said, "I am proud to have chaired the Board as ViaCyte developed into a leading company in the regenerative medicine field.I am confident that Ian's unique expertise and executive leadership, specifically with innovative growth-oriented companies, and specifically in corporate strategy and operations, as well as capital markets will help ViaCyte progress its important work and firmly establish itself as a leader in the cell therapy sector."

About ViaCyte's Pipeline

The PEC-Direct product candidate, currently being evaluated in the clinic, delivers ViaCyte's PEC-01 cells (pancreatic islet progenitor cells) in a non-immunoprotective device and is being developed for type 1 diabetes patients who have hypoglycemia unawareness, extreme glycemic lability, and/or recurrent severe hypoglycemic episodes. The PEC-Encap (also known as VC-01) product candidate, also undergoing clinical evaluation, delivers the same pancreatic islet progenitor cells but in an immunoprotective device. PEC-Encap is being developed for all patients with type 1 diabetes. In collaboration with CRISPR Therapeutics, ViaCyte is developing immune-evasive stem cell lines from its proprietary CyT49 cell line. These immune-evasive stem cell lines, which are being used in the PEC-QT program, have the potential to further broaden the availability of cell therapy for all patients with insulin-requiring diabetes, type 1 and type 2. In addition, a pluripotent, immune evasive cell line has the potential to be used to produce any cell in the body, thus enabling many other potential indications.

About ViaCyte

ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte's product candidates are based on directed differentiation of pluripotent stem cells into PEC-01 pancreatic islet progenitor cells, which are then implanted in durable and retrievable cell delivery devices. Over a decade ago, ViaCyte scientists were the first to report on the production of pancreatic cells from a stem cell starting point and the first to demonstrate in an animal model of diabetes that, once implanted and matured, these cells secrete insulin and other pancreatic hormones in response to blood glucose levels and can be curative. More recently, ViaCyte demonstrated that when effectively engrafted, PEC-01 cells can mature into glucose-responsive insulin producing cells in patients with type 1 diabetes. To accelerate and expand its efforts, ViaCyte has established collaborative partnerships with leading companies including CRISPR Therapeutics and W.L. Gore & Associates. ViaCyte is headquartered in San Diego, California. The Company also has a robust intellectual property portfolio, which includes hundreds of issued patents and pending applications worldwide. ViaCyte is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF. For more information on ViaCyte, please visit http://www.viacyte.comand connect with ViaCyte on Twitter, Facebook, and LinkedIn.

SOURCE ViaCyte, Inc.

Home

Visit link:
ViaCyte Announces $27 Million Financing to Advance Next Generation Cell Therapies for Diabetes - PRNewswire

Breakthrough genome editing companies includingEditas (NASDAQ:EDIT) and Intellia Therapeutics (NASDAQ:NTLA) have been in a tailspin since late 2019, and the latest earnings reports from both of those companies show that their revenue from collaborations and partnerships has started to dry up despite positive revenue growth overall.

Both companies aim to produce gene therapies utilizing CRISPR-based genetic editing in living patients, though their methods of delivering that therapy differ substantially. Neither company has a product on the market, though Editas beat Intellia to clinical trialsin April when it began testing EDIT-101 for Leber congenital amaurosis, a type of congenital blindness. Nonetheless, Editas is many years away from its first therapy being approved for sale, assuming that EDIT-101 proceeds past phase 1.

Investors considering either of these two companies should be aware that both are risky choices with no guarantee of a payoff over any term. There is one significant difference that wise investors will weigh carefully, however: Editas's partnerships and strategic collaborations appear positioned to be far more fruitful for the company than Intellia's.

Image source: Getty Images.

Intellia is a slightly smaller company than Editas, but its pipeline is comparable in breadth. The companies are of similar age, with Editas having been founded in 2013 and Intellia in 2014. However, Intellia's network of collaborations and research partnerships is far less lucrative, and its pipeline projects may soon require new funding to move forward.

Intellia's partners include pharma giantNovartis (NYSE:NVS) and biotechRegeneron (NASDAQ:REGN). Novartis made a substantial equity investment in Intellia as part of that partnership, and Novartis also retained exclusive rights to develop any engineered CAR-T cancer therapies produced by the collaboration. Intellia also agreed to give Regeneron the exclusive right to develop CRISPR-based therapies targeted at any of 10 different genes in the liver.

The terms of these collaborations make Intellia unable to capitalize on major successes beyond extending the depth of integration with its partners. Thus, in the long view, the company's path forward would still require moving its wholly owned therapy candidates to market, even if its approach is proven by a collaborator's success.

Editas's partnerships, on the other hand, are substantially more equitable. Editas's major drug development collaborations include Allergan (now part of AbbVie (NYSE:ABBV) and biopharma giantBristol Myers Squibb (NYSE:BMY). The expectation with these collaborations is that the more mature partner companies will be responsible for clinical-stage development, with Editas providing trial-ready therapy candidates and a technology platform to develop similar therapies according to the partners' needs.

Should these candidates show promise in phase 2 clinical trials investigating preliminary efficacy, the company's collaborators would likely respond by initiating new collaborations to capitalize on Editas's platform before its output is replicated by a competitor like Intellia. But Editas isn't in the same position as Intellia with regard to its major collaborations because it has a chance to capture the upside of collaborators' successes as well.

Editas's collaboration with Allergan specifies that both parties have optionality to co-develop any successful programs, and that Editas will share the revenue and losses of those programs equally with Allergan.And Editas's previous collaborations with companies like Celgene demonstrate that companies collaborating with Editas do so to access its gene-editing platform as customers as much as partners.

Editas also has partnerships with research-stage small preclinical companies such as Sandhill Therapeutics. Sandhill's therapeutic platform could benefit immensely from integrating Editas' genetic editing technologies. A similar research-stage pact with BlueRock Therapeutics initiated in 2019 has already advanced to clinical pipeline collaborations for Editas, proving that working with external peers is one of the company's organizational strengths.

It's important to remember that Editas's collaboration advantage is far from the only ingredient the company needs to survive in the medium term. Reliable revenue remains absent, and collaborations are vulnerable to amendment if the company can't deliver what its collaborators need to move products through the clinical trial process.

Data by YCharts

For the moment, neither Editas nor Intellia warrants a definite buy, and present holders of Intellia may want to consider selling. If Intellia cancels any of its preclinical programs, consider it a strong sign that the company's health is deteriorating. Look at Editas's performance in the second and third quarters to see if they're on the right track for a buy early next year, but understand that waiting until next year to reevaluate the company's situation is probably the wisest path.

View post:
Here's Why Editas Could Beat Intellia to a CRISPR Therapy - Motley Fool

A desperately needed tool to curb the COVID-19 pandemic is an inexpensive home-based rapid testing kit that can detect the coronavirus without needing to go to the hospital.

The Food and Drug Administration has approved a few home sample collection kits but a number of researchers, including myself, are using the gene-editing technique known as CRISPR to make home tests. If they work, these tests could be very accurate and give people an answer in about an hour.

I am a biomolecular scientist with training in pharmaceutical sciences and biomedical engineering and my lab focuses on developing next-generation of technologies for detecting and treating cancer, genetic and infectious diseases.

The COVID-19 disease is caused by a coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Unlike humans which carry their genetic material encoded in DNA, the coronavirus encodes theirs in a related molecule called RNA.

My research group recently engineered a sensitive CRISPR-based technology, that we named CRISPR-ENHANCE, and used it to create a rapid test for SARS-CoV-2 RNA. Our assay works like a pregnancy test and shows two purple colored lines if the sample is positive for the virus. Using our technology, I envision developing a test kit that would allow rapid detection of SARS-CoV-2 RNA in saliva within 45-60 minutes at home without needing any expensive equipment.

The FDA recently gave a green light to a couple of sample collection kits from LabCorp and Everywell under the Emergency Use Authorization (EUA) that would allow people to ship out the nasal swab samples for analysis. Patients can take a swab of their nose, ship the samples to a lab, and wait for a few days to get the results back.

Although not an at-home testing kit, the test allows the samples to be shipped directly to a lab for detecting SARS-CoV-2 RNA. There they use a technique called reverse transcription-polymerase chain reaction (RT-PCR), which converts the viral RNA into DNA so that it can be easily multiplied and detected.

Although most FDA-approved tests are based on detecting SARS-CoV-2 RNA at an early stage, before symptoms even appear, such tests can only be performed in a laboratory setting with expensive equipment and can take multiple days to get the results.

Several antibody testing kits have been approved by the FDA that use a paper-based lateral flow strip, also similar to an at-home pregnancy testing strip, for detecting antibodies called IgM and IgG. Almost all SARS-CoV-2 infected patients make antibodies within 19 days of onset of symptoms and then the body continues to make detectable antibodies for several weeks to months even after symptoms fades away. Therefore, the Centers for Disease Control and Prevention recommends using antibody tests for detecting past infections.

However, the coronavirus is usually very active and contagious in the first week of infection and peaks on the day of onset of symptoms. Therefore, to prevent the spread of coronavirus, it is extremely important to detect coronavirus early to block the spread.

The antibody testing can be great for detecting past infections but they cannot reliably detect current or early infections. The delayed appearance and patient-to-patient variability of antibodies in a blood test further complicates the COVID-19 diagnosis with antibody testing kits.

In addition, the variability between different antibody testing methods have raised doubts about the reliability of these test kits.

Therefore, the National Institutes of Health recently announced a Rapid Acceleration of Diagnostics (RADx) which offers up to US$500 million in funding for ramping up the technologies that detect the SARS-CoV-2 virus.

Most people know of CRISPR/Cas systems as a famous gene-editing technology that can precisely edit DNA. Researchers engineer a guide RNA molecule with a target genetic sequence that serves like a GPS and zooms in on a location on the DNA where a Cas protein, a pair of molecular scissors, can cut at the desired location.

Scientists in the labs of Feng Zhang at MIT, Jennifer Doudna at UC Berkeley and others discovered several newer versions of CRISPR/Cas systems, including ones using the proteins Cas12a and Cas13a-d, which get crazy cutting once they find their match.

My colleagues and I have used this Cas12a-based CRISPR technique to detect the coronavirus.

The coronavirus RNA activates CRISPR/Cas, transforming a pair of controlled molecular scissors into an unstoppable chainsaw. When the the CRISPR/Cas enzyme activates, we know that the genetic sequence of the coronavirus is present in the saliva sample. To make the signal of the coronavirus stronger in the testing kit, we add millions of synthetic reporter molecules which are also chopped up by the CRISPR/Cas mechanism. This means that within minutes we can detect detect the presence of coronavirus.

Under EAU, the FDA recently approved the first CRISPR-based SARS-CoV-2 RNA testing kit from Sherlock Biosciences for testing nasal swabs in a lab. Although not yet approved for at-home testing, this is a big leap toward the development of CRISPR-based diagnostics.

While similar CRISPR-based test kits are in development including one from Mammoth Biosciences and others, our CRISPR-ENHANCE technology relies on engineered CRISPR RNAs that increases the speed of Cas12a chainsaw by between three- and four-fold.

This technique dramatically enhances the sensitivity of detection. Our system can detect fewer virus in a clinical sample faster with a clear visual readout. We are in the process of clinically validating the CRISPR-ENHANCE technology for SARS-CoV-2 RNA detection.

Standard collection method for detecting respiratory viruses in the clinic is the nasal swab. However, coronaviruses have been detected at comparable levels in saliva so some researchers are now turning to saliva for diagnostic testing.

Collecting saliva is not only less invasive than the nasal swabs but also contains more virus, which makes it easier to detect with RT-PCR. In fact, an at-home saliva collection kit just received a green light by the FDA on May 8, 2020. In our validation study we will be internally comparing our test between the nasal swabs and saliva for FDA approval.

We are developing a six-step procedure for home-based testing for saliva along with the nasal swabs. Here is how it would work with saliva.

Spit into a sample collection tube that contains dry chemical reagents that will begin to react with your saliva when you drop the closed tube into the warm water for 30 minutes.

The heat helps the chemicals break up the virus particle and expose the viruss genetic material RNA. The RT-PCR reagents basically multiply the viral RNA creating billions of copies, which are more easily detected.

After 30 minutes, transfer the contents of the collection tube to a second tube containing dried CRISPR components and leave it at room temperature for 10-15 minutes.

Only if CRISPR/Cas finds the specific coronavirus RNA, will it become active and chop up the synthetic reporter molecules that are engineered and added to this second tube. This part happens in just six minutes.

We then drop a paper strip into the second tube. Within 30 seconds one or two purple bands reveal the results.

The health care provider can then direct the individual to either quarantine, isolate and/or recommend further testing such as antibody-based tests. In our study, currently under peer review, we demonstrated that the ENHANCE technology itself is versatile and can also be adopted for detecting a range of targets including HIV, HCV and prostate cancer.

While there are several labs and companies are rushing to develop similar CRISPR-based coronavirus detection kits for saliva testing, we believe our approach offers the fastest detection. We hope to bring the cost of the kit down to between $1 and $2 so that developing countries can also afford a rapid and reliable coronavirus testing kit.

[You need to understand the coronavirus pandemic, and we can help. Read The Conversations newsletter.]

Read this article:
Rapid home-based coronavirus tests are coming together in research labs were working on analyzing spit using advanced CRISPR gene editing techniques...

On May 18, 2020, the Patent Trial and Appeal Board (PTAB) heard argument in Interference No. 106,115,University of California1v. Broad Institute2. The interference involves 10 patent applications of University of California (UC), and 13 patents and one patent application of Broad Institute (Broad), all of which have claims covering CRISPR-Cas9 technology in eukaryotic cells. The hearing took place before a panel of three administrative patent judges, Judge Katz, Judge Lane, and Judge Moore.

A patent interference is a proceeding formerly used to determine who first invented a claimed invention. Interferences were phased out in 2012 legislation, but patents or applications effectively pending before March 2013 still can be subject to an interference.

In January 2017, the PTAB declared a first interference between Broad and UC to determine which party was the first to invent the CRISPR-Cas9 technology. Instead of holding either party as prevailing, the PTAB determined there was no interference-in-fact, because Broad's invention, directed to CRISPR-Cas9 in eukaryotic cells, would not have been obvious from UC's invention, which claims the CRISPR-Cas9 system generically. Hence, the parties' patent claims were not directed to the same invention. The decision was upheld by the Federal Circuit in April 2018.

Shortly after the PTAB decision in the first interference, UC filed patent applications with claims directed to CRISPR-Cas9 system in eukaryotic cells. The newly filed UC claims cover essentially the same scope as Broad's claims that survived the first interference.3The patent examiner decided these claims were otherwise in condition for allowance except for a potential interference with Broad's claims. Subsequently, the PTAB declared the current interference on June 24, 2019.

Typically, one of the parties in an interference is deemed the "senior party," which means the party is entitled to the presumption that it is the prior inventor to make the earliest constructive reduction to practice. Any other party would be a "junior party." Curiously, neither Broad nor UC was accorded the benefit of the priority date of their first provisional application. Rather, both parties were accorded the date of the non-provisional applications involved in the interference, which made Broad the senior party based on dates of their non-provisional applications. Both parties have submitted motions and exhibits to support arguments for the benefit of an earlier priority date, and arguments against the other party's benefit. Most other motions have been deferred until a decision on the issues argued before the PTAB on May 18.

The arguments on May 18, 2020 mainly involved three issues: 1) whether the current interference should be barred by the PTAB's decision in the first interference as affirmed by the Federal Circuit; 2) whether UC should be accorded benefit of the date of its first provisional application (P1); and 3) whether Broad's motion for a different count should be granted.

Regarding the first issue, Broad took the position that the current interference should be barred under the doctrine known as estoppel. Essentially, Broad contended that the current interference proceeding should not have taken place, because the same issues based on same facts were already litigated in the first interference. In rebuttal, UC argued that the legal issue, i.e., whether UC's P1 would have sufficiently enabled a skilled person to use CRISPR-Cas9 in eukaryotic cells, was never litigated or decided.

The first and the second issues are more or less related. According to Broad, even though UC's P1 was not litigated in the first interference, it contained no new facts or experiments other than a laundry list of routine techniques. Broad also pointed to UC's own scientists' frustration and difficulties with CRISPR in eukaryotic cells, which they successfully relied on in the first interference. In response, UC maintained that P1 enclosed all necessary and sufficient components to use CRISPR-Cas9 in eukaryotic cells, because one would only need ordinarily known techniques to make the eukaryotic application. Judge Katz asked if there was anything special about one of the technologies (microinjection in zebrafish embryo, in particular) that UC argued as readily available at the time of P1, but didn't get a clear answer.

The third issue relates to a patent "count." At an early stage of an interference, the PTAB would determine a count, which defines the scope of the proofs for priority. The losing party of an interference would not be entitled to claims patentably indistinct from the count. In the current interference, the original count was directed to a eukaryotic cell comprising CRISPR-Cas9 system with a single guide RNA. Broad has submitted motions for a count that is not limited to single guide RNA only, but covers both single and dual guide RNAs. When UC argued that Broad should be held to the single guide RNA count it originally proposed, Judge Katz questioned the consistency of claim interpretation, as some of Broad's claims would fall out of the scope of the current count.

We expect the PTAB to issue a decision on the above discussed motions in the next one-to-three months. A decision for Broad on estoppel should result in a quick final judgment: the current interference proceeding will then be terminated. If the PTAB decides for UC with accorded benefit of priority, the interference will be redeclared, with UC as the senior party. If either party ends up with a significantly earlier accorded benefit date, the other party might face an order to show cause from the judges, because it would have to prove a massive amount of diligence to get behind the other party's benefit. The PTAB may also decide to change the count based on Broad's claims, or designate certain Broad claims as not corresponding to the count.

If the PTAB makes any decision other than a final judgment or an order to show cause, the parties will likely proceed to a phase where priority is determined, and where the deferred substantive motions may be argued and decided, for example, the parties' motions on patentability and inequitable conduct. Given the history of the patents and applications involved, this next phase could be quite complex and expensive for both parties.

[1] The Regents of the University of California, University of Vienna, and Emmanuelle Charpentier, collectively referred to as UC.

[2]The Broad Institute, Inc., Massachusetts Institute of Technology, and Presidents and Fellows of Harvard College, collectively referred to as Broad.

[3] See, for example, U.S. Patent Application No. 15/981,807, claim 156.

View post:
Patent Trial and Appeal Board Hears Argument in CRISPR Patent Priority Dispute - JD Supra

Researchers are racing against time to find ways to treat and prevent COVID-19. There is currently no treatment for the disease, and the World Health Organisation has created Solidarity, a global clinical trial which is testing four drugs as possible treatment. There are also more than 90 vaccine trials being undertaken worldwide, but it may take more than a year before a vaccine is developed. And there is currently a global shortage of COVID-19 testing kits.

One of the methods researchers are exploring to combat COVID-19 is gene editing. Gene editing could potentially be used on the genome of the virus that causes COVID-19, to make it harmless. It could be used to develop better testing kits, and could even be used to edit the human genome to prevent people from being infected by the virus.

But gene editing is associated with a range of ethical issues such as safety, equal access and consent. Bioethicists and researchers believe that gene editing in humans must be proven to be safe before it can be offered as a treatment option. There is also the issue of equal access to treatment, which must be considered.

To ensure that an ethical approach to research for a cure for COVID-19 is taken, the International Bioethics Committee and the World Commission on the Ethics of Scientific Knowledge and Technology issued a joint statement calling for an interdisciplinary dialogue among scientific, ethical and political stakeholders. The joint statement does not describe specific treatment options, but it calls on the research community to work together to find a cure using a bioethics and ethics of science and technology perspective which is rooted in human rights.

Scientists have considered the possibility of CRISPR (or clustered regularly interspaced short palindromic repeats) technology being used to address the COVID-19 pandemic. CRISPR is a mechanism that arose in bacteria millions of years ago to fight off disease. The CRISPR protein can be used to target specific sequences of DNA, which it then cuts like a pair of scissors. The cut DNA strand can then repair itself, or a new DNA sequence can be inserted. It has now been turned into a biological tool for editing genomes of biological organisms in order to modify them or target disease. It therefore has a number of different uses, from improving crop quality to correcting genetic conditions.

There are three potential ways that CRISPR may help fight COVID-19:

CRISPR has the potential to disable the virus that causes COVID-19 by editing its genome so that it is, in effect, made harmless. Using an approach called PAC-MAN (Prophylactic Antiviral Crispr in huMAN cells), researchers at Stanford University have shown that CRISPR has the ability to attack the SARS-CoV-2 genetic makeup and reduce the amount of virus in a test solution by 90%. Research is ongoing, but its thought that this approach is so effective, it might have the potential to stop the disease in people. There would be no barrier to this research as long as researchers abide by the ethical and legal guidelines that apply to their institution and country.

Gene editing tools have the potential to improve testing rates and could be an answer to the global shortage of COVID-19 tests. Apart from being a gene editing tool, CRISPR is also a diagnostic tool, and can be used to detect infection in cells. Scientists are hopeful that CRISPR based testing will alleviate the global testing burden. While many of these tests are still in the development stage, the Food and Drug Administration approved a CRISPR-based COVID-19 diagnostic test by a Cambridge biotech start-up on 8 May 2020. The test can provide results within an hour, and the company making it claims that more than 1 million tests can be performed in a week. In order for these tests to be legally made available for use, they would need to be approved by the appropriate regulatory authority, such as the Food and Drug Administration in the US, or South Africas Health Products Regulatory Authority.

CRISPR creates the potential to edit peoples genes to make them resistant to infection. So, if we cant stop the virus, can we stop ourselves from getting infected? Gene editing in humans takes one of two forms: somatic cell editing and germline editing.

Somatic cell editing affects a persons body cells, while germline editing involves editing the DNA in sperm, eggs or embryos, resulting in genetic changes in an individuals descendants. There are a number of somatic cell CRISPR clinical trials being undertaken and some treatments have been successful. But germline editing is more controversial and over 40 countries prohibit it in their law.

When the Chinese scientist He Jiankui used CRISPR to edit the genomes of two children, he was criticised as acting unethically, since the safety and efficacy of germline editing has not been established. Scientists around the world called for a five-year moratorium on it. He Jiankui was sentenced to three years in prison in 2019.

There are also laws which will obstruct this potential use of CRISPR. Article 3 of the Oviedo Convention states that an intervention seeking to modify the human genome may only be undertaken for preventive, diagnostic, or therapeutic purposes and only if its aim is not to introduce any modification in the genome of any descendants. This has been interpreted as expressly forbidding germline gene editing.

National law can also prohibit this. Section 57 of South Africas National Health Act states that a person may not manipulate any genetic material, including genetic material of human gametes, zygotes or embryos. Section 57 is enacted to prohibit human reproductive cloning. But this law was enacted before CRISPR even existed and it mimics the approach taken in international law against genetic manipulation of gametes and embryos. There are licensed somatic cell CRISPR therapies available. But there are potential legal barriers to the lasting protection which germline CRISPR intervention would give us.

There is pressure on researchers to develop safe and effective treatment and vaccines. CRISPR technology has been used in a variety of ways, but it raises a series of ethical and legal issues with regard to its potential use in humans.

So far, scientists have been cautious about putting CRISPR technology to use in humans. But should CRISPR be considered as a legitimate weapon in the fight against the pandemic, knowing that time is of the essence? While we all act together in the fight against COVID-19, it cannot be at the expense of ethical and legal standards.

Continue reading here:
COVID-19 and gene editing: ethical and legal considerations - The Conversation Africa

DUBLIN--(BUSINESS WIRE)--The "Global Genome Editing Market By Technique (CRISPR, Zinc Finger Nucleases, TALENs, Restriction enzymes, Others), By Applications (Synthetic Biology, Engineering Cell Line and Organisms, Others), By Source, By End-User, By Region, Forecast & Opportunities, 2025" report has been added to ResearchAndMarkets.com's offering.

The Global Genome Editing Market is expected to grow at a brisk rate during the forecast period owing to growing number of research activities for treatment of various chronic diseases using this technology. Further, increased government funding for genomics technology around the globe, growing preference for personalized medicine and increase in R&D expenditure are fueling the market growth of genome editing.

Genome editing is a way of making specific changes to the DNA of a cell or organism. It could be used to edit the genome of any organism. It uses a type of enzyme called an engineered nuclease' which cuts the genome in a specific place. After cutting the DNA in a specific place, the cell naturally repairs the cut. It finds application in large number of areas, such as mutation, therapeutics, and agriculture biotechnology. Moreover, rise in the number of chronic and infectious diseases is likely to fuel the market for genome editing in the coming years.

The Global Genome Editing market is segmented based on technique, applications, source, end-user and region. Based on applications, the market is segmented into synthetic biology, engineering cell line & organisms, therapeutic genome editing and others. Among them, the cell line engineering is expected to witness the highest growth rate in the coming years due to increase in the number of people suffering with genetic disorders and rising government funding for stem cell research.

Based on end-user, the Global Genome Editing Market is segmented into pharmaceutical & biotechnology companies, clinical research organization and research institutes. Pharmaceutical & biotechnology companies contribute to the largest share of revenue generation for the Global Genome Editing Market. Growing establishments of biotech and pharma companies in emerging economies and growing usage of gene editing technique in research activities undertaken by them to manufacture and develop drugs for rare diseases anticipated to fuel the market across the globe.

Companies Mentioned

Objective of the Study:

Key Topics Covered:

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Global Genome Editing Market Outlook

4.1. Market Size & Forecast

4.2. Market Share & Forecast

4.3. Market Attractiveness Index

5. Asia-Pacific Genome Editing Market Outlook

5.1. Market Size & Forecast

5.2. Market Share & Forecast

5.3. Market Attractiveness Index

5.4. Asia-Pacific: Country Analysis

6. Europe Genome Editing Market Outlook

6.1. Market Size & Forecast

6.2. Market Share & Forecast

6.3. Market Attractiveness Index

6.4. Europe: Country Analysis

7. North America Genome Editing Market Outlook

7.1. Market Size & Forecast

7.2. Market Share & Forecast

7.3. Market Attractiveness Index

7.4. North America: Country Analysis

8. South America Genome Editing Market Outlook

8.1. Market Size & Forecast

8.2. Market Share & Forecast

8.3. Market Attractiveness Index

8.4. South America: Country Analysis

9. Middle East and Africa Genome Editing Market Outlook

9.1. Market Size & Forecast

9.2. Market Share & Forecast

9.3. Market Attractiveness Index

9.4. MEA: Country Analysis

10. Market Dynamics

10.1. Drivers

10.2. Challenges

11. Market Trends & Developments

12. Competitive Landscape

12.1. Competition Outlook

12.2. Players Profiled (Leading Companies)

13. Strategic Recommendations

14. About Us & Disclaimer

For more information about this report visit https://www.researchandmarkets.com/r/tgb83z

Read the original:
Outlook on the Worldwide Genome Editing Industry to 2025 - Featuring Pfizer, Bayer Crop Science & Editas Medicine Among Others -...

Global CRISPR Technology Market 2020 offers detailed research and analysis of the COVID-19 impact provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global CRISPR Technology market. Market participants can use the analysis on market dynamics to plan effective growth strategies and prepare for future challenges beforehand. Each trend of the global CRISPR Technology market is carefully analyzed and researched about by the market analysts.

Click the link to get a Sample Copy of the Report:

https://www.marketinsightsreports.com/reports/05212028897/COVID-19-Impact-on-CRISPR-Technology-Market-Global-Research-Reports-2020-2021/inquiry?source=coleofduty&Mode=48

Top Companies in the Global CRISPR Technology Market: Thermo Fisher Scientific, Merck KGaA, GenScript, Integrated DNA Technologies (IDT), Horizon Discovery Group, Agilent Technologies, Cellecta, GeneCopoeia, New England Biolabs, Origene Technologies, Synthego Corporation, Toolgen

CRISPR technology is a relatively new technology used in genome editing or gene editing; CRISPR-CAS-9 is a palindromic repeats cluster and is found naturally in bacteria. This sequence allows the bacteria to protect them from the virus by producing segments enzyme that cuts RNA or DNA virus and inactivate the virus. This ability of the CRISPR-CAS9 has allowed scientists to make DNA and RNA library as needed and their applications. CRISPR-CAS9 technology has potential applications in treating human disease, creating a gene library, and manipulate cell functions such as metabolism.

Market Segmented by Types:

Enzymes

Kits

gRNA

Libraries

Design Tools

Market Segmented by Applications:

Biomedical

Agricultural

Inquire for Discount:

https://www.marketinsightsreports.com/reports/05212028897/COVID-19-Impact-on-CRISPR-Technology-Market-Global-Research-Reports-2020-2021/discount?source=coleofduty&Mode=48

Regional Analysis:

For comprehensive understanding of market dynamics, the global CRISPR Technology Market is analyzed across key geographies namely: United States, China, Europe, Japan, South-east Asia, India and others. Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

Important Features that are under Offering and Key Highlights of the Reports:

Detailed overview of Market

Changing market dynamics of the industry

In-depth market segmentation by Type, Application etc.

Historical, current and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape of Market

Strategies of key players and product offerings

Potential and niche segments/regions exhibiting promising growth

Take a look at some of the important sections of the report:

Market Overview:It starts with product overview and scope of the global CRISPR Technology market and later gives consumption and production growth rate comparisons by application and product respectively. In addition, it provides statistics related to market size, revenue, and production.

Production Market Share by Region:Apart from the production share of regional markets analyzed in the report, readers are informed about their gross margin, price, revenue, and production growth rate here.

Company Profiles and Key Figures:Each company profiling of leading players operating in the market growth keeping in view vital factors markets served, production sites, price, gross margin, revenue, production, product application, product specification, production sites and product introduction.

Manufacturing Cost Analysis: Readers are provided with detailed manufacturing process analysis, industrial chain analysis, manufacturing cost structure analysis, and raw materials analysis.

Market Dynamics:The analysts explore critical influence factors, market drivers, challenges, risk factors, opportunities, and market trends.

Browse for report description and TOC:

https://www.marketinsightsreports.com/reports/05212028897/COVID-19-Impact-on-CRISPR-Technology-Market-Global-Research-Reports-2020-2021?source=coleofduty&Mode=48

Finally, CRISPR Technology Market report is the believable source for gaining the Market research that will exponentially accelerate your business. The report gives the principle locale, economic situations with the item value, benefit, limit, generation, supply, request and Market development rate and figure and so on. This report additionally Present new task SWOT examination, speculation attainability investigation, and venture return investigation.

Note: All the reports that we list have been tracking the impact of COVID-19. Both upstream and downstream of the entire supply chain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

We Also Offer Customization on report based on specific client Requirement:

Free country Level analysis for any 5 countries of your choice.

Free Competitive analysis of any 5 key market players.

Free 40 analyst hours to cover any other data point.

About Us:

MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact Us:

Irfan Tamboli (Head of Sales) Market Insights Reports

Phone: + 1704 266 3234 | +91-750-707-8687

[emailprotected] | [emailprotected]

See original here:
CRISPR Technology Market Technology Advancements, Overview and Developments in Medical Industry 2020 to 2021 - Cole of Duty

The global Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology market study encloses the projection size of the market both in terms of value (Mn/Bn US$) and volume (x units). With bottom-up and top-down approaches, the report predicts the viewpoint of various domestic vendors in the whole market and offers the market size of the Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology market. The analysts of the report have performed in-depth primary and secondary research to analyze the key players and their market share. Further, different trusted sources were roped in to gather numbers, subdivisions, revenue and shares.

The research study encompasses fundamental points of the global Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology market, from future prospects to the competitive scenario, extensively. The DROT and Porters Five Forces analyses provides a deep explanation of the factors affecting the growth of Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology market. The Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology market has been broken down into various segments, regions, end-uses and players to provide a clear picture of the present market situation to the readers. In addition, the macro- and microeconomic aspects are also included in the research.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2636510&source=atm

The key players covered in this studyThermo Fisher ScientificMerckGenScriptIntegrated DNA TechnologiesHorizon Discovery GroupAgilent TechnologiesCellectaGeneCopoeiaNew England BiolabsOrigene TechnologiesSynthego CorporationToolgen

Market segment by Type, the product can be split intoProductsServicesMarket segment by Application, split intoBiomedical ApplicationsAgricultural ApplicationsIndustrial ApplicationsBiological Research

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

The study objectives of this report are:To analyze global Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology status, future forecast, growth opportunity, key market and key players.To present the Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology are as follows:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year 2020 to 2026For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Purchase reports at discounted prices!!! Offer valid till midnight!!!

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2636510&source=atm

The Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology market research covers an exhaustive analysis of the following data:

The Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology market research addresses critical questions, such as

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2636510&licType=S&source=atm

The global Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology market research considers region 1 (Country 1, country 2), region 2 (Country 1, country 2) and region 3 (Country 1, country 2) as the important segments. All the recent trends, such as changing consumers demand, ecological conservation, and regulatory standards across different regions are covered in the report.

Here is the original post:
COVID-19: Potential impact on Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology Market by Application Analysis 2019-2029 -...

Vertex Pharmaceuticals (VRTX) is the $75 billion champion of cystic fibrosis (CF) who is expected to grow sales 37% this year to $5.7 billion -- after a 37% topline advance last year.

Since 2012, Vertex has developed a suite of drug treatments for CF, including the "triple threat" combo Trikafta, which was approved by the FDA in October 2019.

Cystic fibrosis is a hereditary disease that affects the lungs and digestive system. The body produces thick and sticky mucus that can clog the lungs and obstruct the pancreas. CF can be life-threatening, and people with the condition tend to have a shorter-than-normal life span, with many adults not making it to their 30th birthday.

Vertexs lead marketed products are Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor in combination with ivacaftor), Orkambi (lumacaftor in combination with ivacaftor) and Kalydeco (ivacaftor), which are collectively approved to treat around 60% of the 75,000 CF patients in North America, Europe and Australia.

Trikafta, approved in people aged 12 years and older who have at least one F508del mutation, is under review in Europe and is also being evaluated in younger patients in the United States. With approval of Trikafta, Vertex can address a significantly larger CF patient population almost 90% of patients with CF in the future.

Q1 Quarter and Outlook

Despite COVID-19 related uncertainty, Vertexs sales in 2020 are being driven by rapid uptake of Trikafta and higher international revenues due to reimbursement arrangements in key ex-U.S. countries. Trikaftas early approval and launch was a significant milestone for Vertex.

On April 29, Vertex reported Q1 results and beat estimates for earnings and sales. The 2020 outlook sparked analysts to raise EPS estimates significantly with this year getting boosted 15.8% from $7.60 to $8.80, representing 65% growth.

The company recorded total revenues of $4.16 billion in 2019, up 37%. Orkambi accounted for 29.4% of the companys total product revenues, Kalydeco accounted for 24.7%, Symdeko accounted for 35.4% and Trikafta comprised 10.5% of the same.

Vertexs dependence on the CF franchise for growth is a concern, especially as competitors would only erode market share. But Vertexs non-CF pipeline is progressing rapidly with data in multiple disease arenas expected in 2020: sickle cell disease, thalassemia and pain management.

Vertex + CRISPR = Potential Knockout Punch for Blood Disorders

Vertex is co-developing a gene editing treatment, CTX001 in partnership with CRISPR Therapeutics (CRSP) in two devastating diseases sickle cell disease and thalassemia. Phase I/II studies of CTX001 in adult transfusion-dependent b-thalassemia in Europe and sickle cell disease in the United States are ongoing.

In June 2019, Vertex announced expansion of its collaboration with CRISPR Therapeutics and acquisition of privately held Exonics Therapeutics to boost its gene editing capabilities to develop novel therapies for Duchenne muscular dystrophy (DMD) and Myotonic dystrophy type 1 (DM1).

In the April 29 update, Vertex and partner CRISPR Therapeutics said they remain on track to provide additional data from the two ongoing Phase 1/2 studies of the investigational CRISPR/Cas9 gene-editing therapy CTX001 in patients with transfusion-dependent beta thalassemia and in patients with severe sickle cell disease in 2020.

Bottom line for VRTX: The COVID-19 crisis has put the Biotech sector in the spotlight and dozens of companies are responding with resourceful R&D and robust adaptations to clinical trial interruptions. Vertex is a strong leader here and should be part of any growth-oriented healthcare-focused portfolio.

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.

This outperformance has not just been a recent phenomenon. From 2000 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.

See their latest picks free >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportVertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis ReportCRISPR Therapeutics AG (CRSP) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

View original post here:
Bull of the Day: Vertex Pharma (VRTX) - Yahoo Finance

More than three months into the coronavirus pandemic, widely acknowledged shortcomings with testing continue to hamper the nations recovery. So when a team of microbiologists headed by Dr. Feng Zhang of the McGovern Institute at MIT and the Broad Institute reported this month that they had ironed out a protocol for a simple, cheap, point-of-care test that uses CRISPR to detect the virus, it was hailed as one of the most important contributions to fighting COVID-19.

Efforts to build and scale up a diagnostic have been beset by a number of snags, from a scarcity of chemicals called reagents and equipment to slow return of results. As officials debate how to safely reopen the country, those weaknesses would need to be rectified in a way where relaxing stay-at-home orders doesnt set off a viral rebound.

According to the Harvard Global Health Institute, in order to safely reopen the country and keep it open, we must ramp our testing rate from about a million per week to a million per day. But that remains a stretch by conventional means.

Enter CRISPR, the precision genome-editing technique that is anything but conventional.

Dr. Zhang and his colleagues harnessed a new type of CRISPR to build a test able to rapidly detect as few as 100 coronavirus particles in a swab or saliva sample, according to instructions for the new test, called STOPCovid, that they posted online. The teams focus has now shifted to proving that the test is safe and effective on a mass scale.

Like any diagnostic chemistry, we need to demonstrate that STOPCovid is accurate on a large enough cohort of patient samples to provide benefit, wrote Drs. Jonathan Gootenberg and Omar Abudayyeh, both of the McGovern Institute, in response to emailed questions. In addition, the current pandemic has made clear the need to scale to thousands or millions of tests, and solutions for that are necessary as well.

As to when the new diagnostic may be pressed into service against the novel coronavirus, Its hard to predict what the timeframe would be for a point-of-care or at-home test, the two noted. But given the need for these diagnostics, we would hope at latest by the end of the year.

That timeframe is possible because a prototype for a quick, easy, cheap and precise CRISPR-based diagnostic test had already existed. In 2017 Dr. Zhang and bioengineer Dr. James Collins published research showing that CRISPR could be trained to detect extremely low amounts of genetic material and was suitable for use during disease outbreaks. They dubbed this system Sherlock, for specific high-sensitivity enzymatic reporter unlocking.

Its from that earlier prototype that the new SARS-CoV-2 test takes its cue. STOP stands for Sherlock Testing in One Pot think multiple steps reduced to a single reaction in a tube. Its similar to DNA-targeting CRISPRs, like the well-known Cas9 system for DNA-editing of the human genome. Only this system has been reformulated to target strands of RNA, which are the building blocks of viruses.

Once a guide RNA molecule brings the Cas12 enzymes to the area of interest, the enzymes cut it in such a way that it generates a fluorescent readout. That readout is detectable, in much the same way home pregnancy tests pick up on pregnancy-related hormones.

Broadscale testing of the type afforded by STOPCovid would be integral to reopening the economy again, said Dr. Neville Sanjana, a genome engineer who was not involved in the CRISPR diagnostic research but whose lab, based at the New York Genome Center and NYU, is involved in several efforts using CRISPR, both COVID-related and non.

The CRISPR-based diagnostics do present a path forward not just to scaling up but to longitudinal sampling, continual sampling, said Dr. Sanjana, who, in addition to being a faculty member at the New York Genome Center, is also assistant professor of biology at New York University and of neuroscience and physiology at the NYU School of Medicine. Were only going to feel comfortable going back to work if not only do you know that your coworker was Covid-negative yesterday, but you know your coworker was Covid-negative last week and Covid-negative today if you have as many assurances as possible.

To fully appreciate why a CRISPR-based test might be a good fit in this situation requires a comparison to the standard COVID-19 test, which is based on a technology called qPCR. The qPCR tests work by detecting nucleic acids, like RNA, and amplifying them. In that sense, theyre similar to CRISPR-based tests.

However, thats where the similarities end.

The qPCR tests require a specialized piece of equipment combining a thermocycler (a machine that automatically cycles through multiple temperature changes) and a microscope. These machines are typically only found in labs and normally cost a few thousand dollars apiece. The other big limitation of qPCR is that the reagents needed to perform the test require cold storage.

CRISPR-based diagnostics, on the other hand, can assay the presence or absence of a nucleic acid at just one temperature. In addition, its been demonstrated also by Dr. Zhang and colleagues that its possible to freeze-dry CRISPR enzymes, obviating the need for cumbersome cold storage.

You dont need the microbiology lab. Instead, you maybe need a stove, said Sanjana.

One of the unique aspects of CRISPR is that it enables sensitive detection without requiring fancy equipment or refrigerated storage.

Reading the results is relatively simple, too. Whereas qPCR and PCR-based test results must be read out either using a microscope or something called agarose gel electrophoresis another lab mainstay the CRISPR-based assay for SARS-CoV-2 uses a lateral flow strip for readout, akin to a home pregnancy test.

A test strip is placed in a tube, and the presence of two lines indicates SARS-CoV-2. Results come in about an hour, the researchers say, with no special handling needed. A mobile phone app can analyze images captured by the phone camera to readout test results, they noted in their white paper.

That [kind of straightforward readout] would be an enabling technology, said Sanjana, even in places located close to a traditional lab.

Whats more, STOPCovid tested on a nasopharyngeal swab bested sensitivity and specificity rates of qPCR, according to Zhangs team (its been shown to work in saliva, too). His group has prepared reagents for 10,000 tests to make freely available to other researchers who want to evaluate its diagnostic use.

At least two other research groups are studying CRISPR technologys promise in diagnosing coronavirus. The FDA was suitably impressed with the test coming out of the Broad group, which is being commercialized through a company aptly named Sherlock, that the agency handed it an emergency use authorization this month. Meanwhile, Zhang is reportedly talking to would-be commercial partners about designing a device based on a disposable, single-use test cartridge, similar to a pregnancy test.

Thats the kind of thing we want, said Dr. Sanjana. If I had to think about what would be the ideal test, it would be something that would be dirt cheap, you could do it every single day, you could test yourself and your whole family, and youd get results instantly or close to instantly. This is what we need to go back to work safely.

Not to say that the CRISPR-based testing is the end-all-be-all, he added, but I think it can fill a very unique niche, even in places where you might have access to what you need to do qPCR-based tests. But the convenience would be greater and thus the adoption would be better.

Here is the original post:
A CRISPR-based, at-home COVID-19 test is set to arrive this year. Here's what you need to know - News - MM&M - Medical Marketing and Media

The recent outbreak of the COVID-19 (Coronavirus) pandemic has built and broken many value-grab opportunities for companies in the CRISPR and Cas Genes market. Gain full access on our latest analysis about COVID-19 and how companies in the CRISPR and Cas Genes market are capitalizing on new strategies to maintain stable revenue income. Look into our resourceful insights highlighting the impact of COVID-19 caused on the global market landscape.

Why Choose MRRSE Research?

Request Sample Report @https://www.mrrse.com/sample/17251?source=atm

The report on the global CRISPR and Cas Genes market published by Market Research Reports Search Engine(MRRSE) provides a clear understanding of the flight of the CRISPR and Cas Genes market over the forecast period (20XX-20XX). The study introspects the various factors that are tipped to influence the growth of the CRISPR and Cas Genes market in the upcoming years. The current trends, growth opportunities, restraints, and major challenges faced by market players in the CRISPR and Cas Genes market are analyzed in the report.

The study reveals that the global CRISPR and Cas Genes market is projected to reach a market value of ~US$XX by the end of 20XX and grow at a CAGR of ~XX% during the assessment period. Further, a qualitative and quantitative analysis of the CRISPR and Cas Genes market based on data collected from various credible sources in the market value chain is included in the report along with relevant tables, graphs, and figures.

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/17251?source=atm

Key Takeaways of the Report:

CRISPR and Cas Genes Market Segmentation

By Region

The presented study throws light on the current and future prospects of the CRISPR and Cas Genes market in various geographies such as:

By Product Type

The report highlights the product adoption pattern of various products in the CRISPR and Cas Genes market and provides intricate insights such as the consumption volume, supply-demand ratio, and pricing models of the following products:

Companies Mentioned in the Report

The report also profiles the major players in the market in terms of various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Key players operating in the global CRISPR and Cas genes market include Synthego, Thermo Fisher Scientific, Inc., GenScript, Addgene, Merck KGaA (Sigma-Aldrich), Integrated DNA Technologies, Inc., Transposagen Biopharmaceuticals, Inc., OriGene Technologies, Inc., New England Biolabs, Dharmacon, Cellecta, Inc., Agilent Technologies, and Applied StemCell Inc. These players are adopting organic and in-organic growth strategies to expand product offerings, strengthen geographical reach, increase customer base, and market share.

The global CRISPR and Cas genes market has been segmented as follows:

Global CRISPR and Cas Genes Market, by Product

Global CRISPR and Cas Genes Market, by Application

Global CRISPR and Cas Genes Market, by End-user

Global CRISPR and Cas Genes Market, by Region

Buy This Report @ https://www.mrrse.com/checkout/17251?source=atm

The report addresses the following doubts related to the CRISPR and Cas Genes market:

Here is the original post:
The impact of the coronavirus on the CRISPR and Cas Genes Market 2020:Key Insights, Drivers and Restraints, Opportunities and Challenges, Sales and...

After William Blair and Piper Sandler gave Crispr Therapeutics AG (NASDAQ: CRSP) a Buy rating last month, the company received another Buy, this time from Oppenheimer. Analyst Jay Olson maintained a Buy rating on Crispr Therapeutics AG yesterday and set a price target of $80.00. The companys shares closed last Friday at $61.09.

According to TipRanks.com, Olson is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -7.8% and a 39.0% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, ACADIA Pharmaceuticals, and Enanta Pharmaceuticals.

Currently, the analyst consensus on Crispr Therapeutics AG is a Moderate Buy with an average price target of $71.83, a 28.8% upside from current levels. In a report issued on May 6, Chardan Capital also reiterated a Buy rating on the stock.

See todays analyst top recommended stocks >>

The company has a one-year high of $74.00 and a one-year low of $32.30. Currently, Crispr Therapeutics AG has an average volume of 967.6K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.

Read this article:
Crispr Therapeutics AG (CRSP) Received its Third Buy in a Row - Smarter Analyst

A new business intelligence report released by CMI with title Global CRISPR and CAS Gene Market Research Report 2020-2027 is designed covering micro level of analysis by manufacturers and key business segments. The Global CRISPR and CAS Gene Market survey analysis offers energetic visions to conclude and study market size, market hopes, and competitive surroundings. The research is derived through primary and secondary statistics sources and it comprises both qualitative and quantitative detailing. Some of the key players profiled in the study are Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio Inc., Synthego, Thermo Fisher Scientific, Inc., GenScript, Addgene, Merck KGaA (Sigma-Aldrich), Integrated DNA Technologies, Inc., Transposagen Biopharmaceuticals, Inc., OriGene Technologies, Inc., New England Biolabs, Dharmacon, Cellecta, Inc., Agilent Technologies, and Applied StemCell, Inc.

Whats keeping Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio Inc., Synthego, Thermo Fisher Scientific, Inc., GenScript, Addgene, Merck KGaA (Sigma-Aldrich), Integrated DNA Technologies, Inc., Transposagen Biopharmaceuticals, Inc., OriGene Technologies, Inc., New England Biolabs, Dharmacon, Cellecta, Inc., Agilent Technologies, and Applied StemCell, Inc. Ahead in the Market? Benchmark yourself with the strategic moves and findings recently released by CMI

Get Summery Of this Report:https://www.coherentmarketinsights.com/market-insight/crispr-and-cas-gene-market-2598

Market Overview of Global CRISPR and CAS Gene

If you are involved in the Global CRISPR and CAS Gene industry or aim to be, then this study will provide you inclusive point of view. Its vital you keep your market knowledge up to date segmented by Applications and major players. If you have a different set of players/manufacturers according to geography or needs regional or country segmented reports we can provide customization according to your requirement.

This study mainly helps understand which market segments or Region or Country they should focus in coming years to channelize their efforts and investments to maximize growth and profitability. The report presents the market competitive landscape and a consistent in depth analysis of the major vendor/key players in the market.

Detailed Segmentation:

By Product Type:Vector-based CasDNA-free CasGlobal CRISPR and CAS Gene Market, By Application:Genome EngineeringDisease modelsFunctional GenomicsKnockdown/activationOther Applications

Regions included:

o North America (United States, Canada, and Mexico)

o Europe (Germany, France, UK, Russia, and Italy)

o Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)

o South America (Brazil, Argentina, Colombia)

o Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Key Benefits:

o This study gives a detailed analysis of drivers and factors limiting the market expansion of CRISPR and CAS Gene

o The micro-level analysis is conducted based on its product types, end-user applications, and geographies

o Porters five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players

o By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this CRISPR and CAS Gene market

The PDF Research only provides Table of Contents (ToC), scope of the report and research framework of the report.

Get PDF brochure of this report: https://www.coherentmarketinsights.com/insight/request-pdf/2598

The research study can answer the following Key questions:

Table of Contents

Report Overview: It includes the CRISPR and CAS Gene market study scope, players covered, key market segments, market analysis by application, market analysis by type, and other chapters that give an overview of the research study.

Executive Summary: This section of the report gives information about CRISPR and CAS Gene market trends and shares, market size analysis by region and analysis of global market size. Under market size analysis by region, analysis of market share and growth rate by region is provided.

Profiles of International Players: Here, key players of the CRISPR and CAS Gene market are studied on the basis of gross margin, price, revenue, corporate sales, and production. This section gives a business overview of the players and shares their important company details.

Regional Study: All of the regions and countries analyzed in the CRISPR and CAS Gene market report is studied on the basis of market size by application, the market size by product, key players, and market forecast.

We Do Offer Sample of this report. Kindly go through the follow information in order to access the report.

Note- This report sample includes:

Brief Introduction to the research report.

Table of Contents (Scope covered as a part of the study)

Top players in the market

Research framework (presentation)

Research methodology adopted by CMI

Request sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2598

An Overview of the Impact of COVID-19 on this Market:

The pandemic of COVID-19 continues to expand and impact over 175 countries and territories. Although the outbreak appears to have slowed in China, COVID-19 has impacted globally. The pandemic could affect three main aspects of the global economy: production, supply chain, and firms and financial markets. National governments have announced largely uncoordinated, country-specific responses to the virus. As authorities encourage social distancing and consumers stay indoors, several businesses are hit. However, coherent, coordinated, and credible policy responses are expected to offer the best chance at limiting the economic fallout.

National governments and international bodies are focused on adopting collaborative efforts to encourage financial institutions to meet the financial needs of customers and members affected by the coronavirus. However, there are some sectors that have remained unscathed from the impact of the pandemic and there are some that are hit the hardest.

Reasons to Purchase CRISPR and CAS Gene report is:

Gives a complete understanding of the CRISPR and CAS Gene Market to express competitor information, analysis, and insights to formulate effective RD strategies.

Collect data of the developing participants having the potentially profitable portfolio in this space and create effective counter-strategies to gain competitive benefits.

Note: Access insightful study with over 150+ pages, list of tables & figures, profiling 20+ companies.

Buy This Complete A Business Report: https://www.coherentmarketinsights.com/insight/buy-now/2598

Thanks For Reading This Article; You Can Also Get Individual Chapter Wise Section Or Region Wise Report Versions Like North America, Europe Or Southeast Asia Or Just Eastern Asia.

**Be Safe and Stay Home**

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contacts US:

Mr. ShahCoherent Market Insights,1001 4th Ave,#3200 Seattle, WA 98154, U.S.Email:sales@coherentmarketinsights.comPhone: US +1-206-701-6702/UK +44-020 8133 4027

Link:
CRISPR and CAS Gene Market to Witness Huge Growth by 2027 | Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio...

The shares of CRISPR Therapeutics AG (NASDAQ:CRSP) has been pegged with a rating of Hold by Stifel in its latest research note that was published on March 05, 2020. The Healthcare company has also assigned a $52 price target. Stifel wasnt the only research firm that published a report of CRISPR Therapeutics AG, with other equities research analysts also giving their opinion on the stock. Evercore ISI advised investors in its research note published on February 03, 2020, to In-line the CRSP stock while also putting a $52 price target. The stock had earned Outperform rating from William Blair Markets when it published its report on November 19, 2019. The stock was given Outperform rating by Oppenheimer in its report released on November 12, 2019, the day when the price target on the stock was placed at 65. Jefferies was of a view that CRSP is Buy in its latest report on August 01, 2019. Canaccord Genuity thinks that CRSP is worth Buy rating. This was contained in the firms report on July 26, 2019 in which the stocks price target was also moved to 72.

Amongst the analysts that rated the stock, 2 have recommended investors to sell it, 4 believe it has the potential for further growth, thus rating it as Hold while 11 advised investors to purchase the stock. The price of the stock the last time has raised by 89.13% from its 52-Week high price while it is -17.45% than its 52-Week low price. A look at the stocks other technical shows that its 14-day RSI now stands at 66.89.

The shares of the company added by 9.32% during the trading session on Friday, reaching a low of $54.86 while ending the day at $61.09. During the trading session, a total of 1.03 million shares were traded which represents a -6.22% decline from the average session volume which is 0.97 million shares. CRSP had ended its last session trading at $55.88. CRISPR Therapeutics AG debt-to-equity ratio currently stands at 0.00, while its quick ratio hovers at 16.90 CRSP 52-week low price stands at $32.30 while its 52-week high price is $74.00.

The company in its last quarterly report recorded -$1.15 earnings per share which is below the predicted by most analysts. The CRISPR Therapeutics AG generated 889.71 million in revenue during the last quarter. In the second quarter last year, the firm recorded $0.51 earnings per share. Compared to the same quarter last year, the firms revenue was up by 12.17%. CRISPR Therapeutics AG has the potential to record -4.51 EPS for the current fiscal year, according to equities analysts.

Investment analysts at BofA/Merrill published a research note on May 15, 2020 where it informed investors and clients that Canada Goose Holdings Inc. (NYSE:GOOS) is now rated as Underperform. Even though the stock has been trading at $20.70/share, analysts expect it to down by -7.15% to reach $32.90/share. It started the day trading at $19.74 and traded between $18.52 and $19.22 throughout the trading session.

A look at its technical shows that GOOSs 50-day SMA is 20.58 while its 200-day SMA stands at 33.10. The stock has a high of $51.71 for the year while the low is $12.94. The stock, however, witnessed a rise in its short on 04/30/20. Compared to previous close which recorded 10.25 M shorted shares, the short percentage went lower by -6.05%, as 9.63M CRSP shares were shorted. At the moment, only 16.46% of Canada Goose Holdings Inc. shares were sold short. The companys P/E ratio currently sits at 28.14, while the P/B ratio is 9.99. The companys average trading volume currently stands at 2.23M shares, which means that the short-interest ratio is just 4.32 days. Over the past seven days, the company moved, with its shift of -15.74%. Looking further, the stock has dropped -38.00% over the past 90 days while it lost -44.79% over the last six months.

Morgan Stanley Asia Ltd. (Investm meanwhile bought more GOOS shares in the recently filed quarter, changing its stake to $162,992,259 worth of shares.

Following these latest developments, around 0.71% of Canada Goose Holdings Inc. stocks are owned by institutional investors and hedge funds.

Follow this link:
Mixed Analyst Attention: CRISPR Therapeutics AG (NASDAQ:CRSP), Canada Goose Holdings Inc. (NYSE:GOOS) - State Reviewer

ZUG, Switzerland and CAMBRIDGE, Mass., May 15, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that four abstracts have been accepted for poster presentation at the American Association for Cancer Research (AACR) Virtual Annual Meeting II, which will take place from June 22 to 24, 2020.

Session information is available online via the Annual Meeting Itinerary Planner through the AACR website at http://www.aacr.org.

Title: Functional and single-cell assessment of CRISPR-modified CAR-T cells from NSCLC patients and healthy donors Session Title: Adoptive Cell Therapy 1 E-Poster Number: 879 Abstract Number: 3338

Title: Allogeneic CAR-T cell products containing 10 gene edits using CRISPR/Cas9 can retain full functionality in vivo and in vitro Session Title: Adoptive Cell Therapy 1 E-Poster Number: 880 Abstract Number: 4647

Title: Allogeneic anti-PTK7 CAR-T cells for the treatment of solid tumors Session Title: Adoptive Cell Therapy 3 E-Poster Number: 3243 Abstract Number: 6231

Title: Targeting T cell lymphomas with CRISPR/Cas9-generated anti-CD70 allogeneic CAR-T cells Session Title: Adoptive Cell Therapy 5 E-Poster Number: 6595 Abstract Number: 3308

About CRISPR Therapeutics CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit http://www.crisprtx.com.

CRISPR Investor Contact: Susan Kim +1 617-307-7503 susan.kim@crisprtx.com

CRISPR Media Contact: Rachel Eides WCG on behalf of CRISPR +1 617-337-4167 reides@wcgworld.com

More here:
CRISPR Therapeutics Announces Presentations at the American Association for Cancer Research 2020 Annual Meeting - Stockhouse

Los Angeles, United StatesThe report offers an all-inclusive and accurate research study on the global CRISPR And CRISPR-Associated (Cas) Genes market while chiefly focusing on current and historical market scenarios. Stakeholders, market players, investors, and other market participants can significantly benefit from the thorough market analysis provided in the report. The authors of the report have compiled a detailed study on crucial market dynamics, including growth drivers, restraints, and opportunities. This study will help market participants to get a good understanding of future development of the global CRISPR And CRISPR-Associated (Cas) Genes market. The report also focuses on market taxonomy, regional analysis, opportunity assessment, and vendor analysis to help with comprehensive evaluation of the global CRISPR And CRISPR-Associated (Cas) Genes market.

Key companies operating in the global CRISPR And CRISPR-Associated (Cas) Genes market include : , Caribou Biosciences, Addgene, CRISPR THERAPEUTICS, Merck KGaA, Mirus Bio LLC, Editas Medicine, Takara Bio USA, Thermo Fisher Scientific, Horizon Discovery Group, Intellia Therapeutics, GE Healthcare Dharmacon CRISPR And CRISPR-Associated (Cas) Genes

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1704011/covid-19-impact-on-global-crispr-and-crispr-associated-cas-genes-market

Segment Analysis

The segmental analysis will help companies to focus on high-growth areas of the global CRISPR And CRISPR-Associated (Cas) Genes market. In order to broaden the overall understanding of the global CRISPR And CRISPR-Associated (Cas) Genes industry, the report has segregated the global CRISPR And CRISPR-Associated (Cas) Genes business into varied segments comprising product type, application, and end user. This examination has been carried out based on parameters like size, CAGR, share, production, and consumption. Also, region-wise assessment, wherein lucrative prospects that a region or country is likely to offer has been explored.

Global CRISPR And CRISPR-Associated (Cas) Genes Market Segment By Type:

, Genome Editing, Genetic engineering, gRNA Database/Gene Librar, CRISPR Plasmid, Human Stem Cells, Genetically Modified Organisms/Crops, Cell Line Engineering CRISPR And CRISPR-Associated (Cas) Genes

Global CRISPR And CRISPR-Associated (Cas) Genes Market Segment By Application:

, Genome Editing, Genetic engineering, gRNA Database/Gene Librar, CRISPR Plasmid, Human Stem Cells, Genetically Modified Organisms/Crops, Cell Line Engineering CRISPR And CRISPR-Associated (Cas) Genes

Competitive Landscape:

It is important for every market participant to be familiar with the competitive scenario in the global CRISPR And CRISPR-Associated (Cas) Genes industry. In order to fulfill the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Key companies operating in the global CRISPR And CRISPR-Associated (Cas) Genes market include : , Caribou Biosciences, Addgene, CRISPR THERAPEUTICS, Merck KGaA, Mirus Bio LLC, Editas Medicine, Takara Bio USA, Thermo Fisher Scientific, Horizon Discovery Group, Intellia Therapeutics, GE Healthcare Dharmacon CRISPR And CRISPR-Associated (Cas) Genes

Key Questions Answered

Enquire for Customization in this Report: https://www.qyresearch.com/customize-request/form/1704011/covid-19-impact-on-global-crispr-and-crispr-associated-cas-genes-market

Table of Contents

1 Study Coverage1.1 CRISPR And CRISPR-Associated (Cas) Genes Product Introduction1.2 Market Segments1.3 Key CRISPR And CRISPR-Associated (Cas) Genes Manufacturers Covered: Ranking by Revenue1.4 Market by Type1.4.1 Global CRISPR And CRISPR-Associated (Cas) Genes Market Size Growth Rate by Type1.4.2 Genome Editing1.4.3 Genetic engineering1.4.4 gRNA Database/Gene Librar1.4.5 CRISPR Plasmid1.4.6 Human Stem Cells1.4.7 Genetically Modified Organisms/Crops1.4.8 Cell Line Engineering1.5 Market by Application1.5.1 Global CRISPR And CRISPR-Associated (Cas) Genes Market Size Growth Rate by Application1.5.2 Biotechnology Companies1.5.3 Pharmaceutical Companies1.5.4 Academic Institutes1.5.5 Research and Development Institutes1.6 Coronavirus Disease 2019 (Covid-19): CRISPR And CRISPR-Associated (Cas) Genes Industry Impact1.6.1 How the Covid-19 is Affecting the CRISPR And CRISPR-Associated (Cas) Genes Industry

1.6.1.1 CRISPR And CRISPR-Associated (Cas) Genes Business Impact Assessment Covid-19

1.6.1.2 Supply Chain Challenges

1.6.1.3 COVID-19s Impact On Crude Oil and Refined Products1.6.2 Market Trends and CRISPR And CRISPR-Associated (Cas) Genes Potential Opportunities in the COVID-19 Landscape1.6.3 Measures / Proposal against Covid-19

1.6.3.1 Government Measures to Combat Covid-19 Impact

1.6.3.2 Proposal for CRISPR And CRISPR-Associated (Cas) Genes Players to Combat Covid-19 Impact1.7 Study Objectives1.8 Years Considered 2 Executive Summary2.1 Global CRISPR And CRISPR-Associated (Cas) Genes Market Size Estimates and Forecasts2.1.1 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue 2015-20262.1.2 Global CRISPR And CRISPR-Associated (Cas) Genes Sales 2015-20262.2 CRISPR And CRISPR-Associated (Cas) Genes Market Size by Region: 2020 Versus 20262.2.1 Global CRISPR And CRISPR-Associated (Cas) Genes Retrospective Market Scenario in Sales by Region: 2015-20202.2.2 Global CRISPR And CRISPR-Associated (Cas) Genes Retrospective Market Scenario in Revenue by Region: 2015-2020 3 Global CRISPR And CRISPR-Associated (Cas) Genes Competitor Landscape by Players3.1 CRISPR And CRISPR-Associated (Cas) Genes Sales by Manufacturers3.1.1 CRISPR And CRISPR-Associated (Cas) Genes Sales by Manufacturers (2015-2020)3.1.2 CRISPR And CRISPR-Associated (Cas) Genes Sales Market Share by Manufacturers (2015-2020)3.2 CRISPR And CRISPR-Associated (Cas) Genes Revenue by Manufacturers3.2.1 CRISPR And CRISPR-Associated (Cas) Genes Revenue by Manufacturers (2015-2020)3.2.2 CRISPR And CRISPR-Associated (Cas) Genes Revenue Share by Manufacturers (2015-2020)3.2.3 Global CRISPR And CRISPR-Associated (Cas) Genes Market Concentration Ratio (CR5 and HHI) (2015-2020)3.2.4 Global Top 10 and Top 5 Companies by CRISPR And CRISPR-Associated (Cas) Genes Revenue in 20193.2.5 Global CRISPR And CRISPR-Associated (Cas) Genes Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.3 CRISPR And CRISPR-Associated (Cas) Genes Price by Manufacturers3.4 CRISPR And CRISPR-Associated (Cas) Genes Manufacturing Base Distribution, Product Types3.4.1 CRISPR And CRISPR-Associated (Cas) Genes Manufacturers Manufacturing Base Distribution, Headquarters3.4.2 Manufacturers CRISPR And CRISPR-Associated (Cas) Genes Product Type3.4.3 Date of International Manufacturers Enter into CRISPR And CRISPR-Associated (Cas) Genes Market3.5 Manufacturers Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026)4.1 Global CRISPR And CRISPR-Associated (Cas) Genes Market Size by Type (2015-2020)4.1.1 Global CRISPR And CRISPR-Associated (Cas) Genes Sales by Type (2015-2020)4.1.2 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue by Type (2015-2020)4.1.3 CRISPR And CRISPR-Associated (Cas) Genes Average Selling Price (ASP) by Type (2015-2026)4.2 Global CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast by Type (2021-2026)4.2.1 Global CRISPR And CRISPR-Associated (Cas) Genes Sales Forecast by Type (2021-2026)4.2.2 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue Forecast by Type (2021-2026)4.2.3 CRISPR And CRISPR-Associated (Cas) Genes Average Selling Price (ASP) Forecast by Type (2021-2026)4.3 Global CRISPR And CRISPR-Associated (Cas) Genes Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Breakdown Data by Application (2015-2026)5.1 Global CRISPR And CRISPR-Associated (Cas) Genes Market Size by Application (2015-2020)5.1.1 Global CRISPR And CRISPR-Associated (Cas) Genes Sales by Application (2015-2020)5.1.2 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue by Application (2015-2020)5.1.3 CRISPR And CRISPR-Associated (Cas) Genes Price by Application (2015-2020)5.2 CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast by Application (2021-2026)5.2.1 Global CRISPR And CRISPR-Associated (Cas) Genes Sales Forecast by Application (2021-2026)5.2.2 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue Forecast by Application (2021-2026)5.2.3 Global CRISPR And CRISPR-Associated (Cas) Genes Price Forecast by Application (2021-2026) 6 North America6.1 North America CRISPR And CRISPR-Associated (Cas) Genes by Country6.1.1 North America CRISPR And CRISPR-Associated (Cas) Genes Sales by Country6.1.2 North America CRISPR And CRISPR-Associated (Cas) Genes Revenue by Country6.1.3 U.S.6.1.4 Canada6.2 North America CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Type6.3 North America CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Application 7 Europe7.1 Europe CRISPR And CRISPR-Associated (Cas) Genes by Country7.1.1 Europe CRISPR And CRISPR-Associated (Cas) Genes Sales by Country7.1.2 Europe CRISPR And CRISPR-Associated (Cas) Genes Revenue by Country7.1.3 Germany7.1.4 France7.1.5 U.K.7.1.6 Italy7.1.7 Russia7.2 Europe CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Type7.3 Europe CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Application 8 Asia Pacific8.1 Asia Pacific CRISPR And CRISPR-Associated (Cas) Genes by Region8.1.1 Asia Pacific CRISPR And CRISPR-Associated (Cas) Genes Sales by Region8.1.2 Asia Pacific CRISPR And CRISPR-Associated (Cas) Genes Revenue by Region8.1.3 China8.1.4 Japan8.1.5 South Korea8.1.6 India8.1.7 Australia8.1.8 Taiwan8.1.9 Indonesia8.1.10 Thailand8.1.11 Malaysia8.1.12 Philippines8.1.13 Vietnam8.2 Asia Pacific CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Type8.3 Asia Pacific CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Application 9 Latin America9.1 Latin America CRISPR And CRISPR-Associated (Cas) Genes by Country9.1.1 Latin America CRISPR And CRISPR-Associated (Cas) Genes Sales by Country9.1.2 Latin America CRISPR And CRISPR-Associated (Cas) Genes Revenue by Country9.1.3 Mexico9.1.4 Brazil9.1.5 Argentina9.2 Central & South America CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Type9.3 Central & South America CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Application 10 Middle East and Africa10.1 Middle East and Africa CRISPR And CRISPR-Associated (Cas) Genes by Country10.1.1 Middle East and Africa CRISPR And CRISPR-Associated (Cas) Genes Sales by Country10.1.2 Middle East and Africa CRISPR And CRISPR-Associated (Cas) Genes Revenue by Country10.1.3 Turkey10.1.4 Saudi Arabia10.1.5 UAE10.2 Middle East and Africa CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Type10.3 Middle East and Africa CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Application 11 Company Profiles11.1 Caribou Biosciences11.1.1 Caribou Biosciences Corporation Information11.1.2 Caribou Biosciences Description, Business Overview and Total Revenue11.1.3 Caribou Biosciences Sales, Revenue and Gross Margin (2015-2020)11.1.4 Caribou Biosciences CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.1.5 Caribou Biosciences Recent Development11.2 Addgene11.2.1 Addgene Corporation Information11.2.2 Addgene Description, Business Overview and Total Revenue11.2.3 Addgene Sales, Revenue and Gross Margin (2015-2020)11.2.4 Addgene CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.2.5 Addgene Recent Development11.3 CRISPR THERAPEUTICS11.3.1 CRISPR THERAPEUTICS Corporation Information11.3.2 CRISPR THERAPEUTICS Description, Business Overview and Total Revenue11.3.3 CRISPR THERAPEUTICS Sales, Revenue and Gross Margin (2015-2020)11.3.4 CRISPR THERAPEUTICS CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.3.5 CRISPR THERAPEUTICS Recent Development11.4 Merck KGaA11.4.1 Merck KGaA Corporation Information11.4.2 Merck KGaA Description, Business Overview and Total Revenue11.4.3 Merck KGaA Sales, Revenue and Gross Margin (2015-2020)11.4.4 Merck KGaA CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.4.5 Merck KGaA Recent Development11.5 Mirus Bio LLC11.5.1 Mirus Bio LLC Corporation Information11.5.2 Mirus Bio LLC Description, Business Overview and Total Revenue11.5.3 Mirus Bio LLC Sales, Revenue and Gross Margin (2015-2020)11.5.4 Mirus Bio LLC CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.5.5 Mirus Bio LLC Recent Development11.6 Editas Medicine11.6.1 Editas Medicine Corporation Information11.6.2 Editas Medicine Description, Business Overview and Total Revenue11.6.3 Editas Medicine Sales, Revenue and Gross Margin (2015-2020)11.6.4 Editas Medicine CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.6.5 Editas Medicine Recent Development11.7 Takara Bio USA11.7.1 Takara Bio USA Corporation Information11.7.2 Takara Bio USA Description, Business Overview and Total Revenue11.7.3 Takara Bio USA Sales, Revenue and Gross Margin (2015-2020)11.7.4 Takara Bio USA CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.7.5 Takara Bio USA Recent Development11.8 Thermo Fisher Scientific11.8.1 Thermo Fisher Scientific Corporation Information11.8.2 Thermo Fisher Scientific Description, Business Overview and Total Revenue11.8.3 Thermo Fisher Scientific Sales, Revenue and Gross Margin (2015-2020)11.8.4 Thermo Fisher Scientific CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.8.5 Thermo Fisher Scientific Recent Development11.9 Horizon Discovery Group11.9.1 Horizon Discovery Group Corporation Information11.9.2 Horizon Discovery Group Description, Business Overview and Total Revenue11.9.3 Horizon Discovery Group Sales, Revenue and Gross Margin (2015-2020)11.9.4 Horizon Discovery Group CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.9.5 Horizon Discovery Group Recent Development11.10 Intellia Therapeutics11.10.1 Intellia Therapeutics Corporation Information11.10.2 Intellia Therapeutics Description, Business Overview and Total Revenue11.10.3 Intellia Therapeutics Sales, Revenue and Gross Margin (2015-2020)11.10.4 Intellia Therapeutics CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.10.5 Intellia Therapeutics Recent Development11.1 Caribou Biosciences11.1.1 Caribou Biosciences Corporation Information11.1.2 Caribou Biosciences Description, Business Overview and Total Revenue11.1.3 Caribou Biosciences Sales, Revenue and Gross Margin (2015-2020)11.1.4 Caribou Biosciences CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.1.5 Caribou Biosciences Recent Development 12 Future Forecast by Regions (Countries) (2021-2026)12.1 CRISPR And CRISPR-Associated (Cas) Genes Market Estimates and Projections by Region12.1.1 Global CRISPR And CRISPR-Associated (Cas) Genes Sales Forecast by Regions 2021-202612.1.2 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue Forecast by Regions 2021-202612.2 North America CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast (2021-2026)12.2.1 North America: CRISPR And CRISPR-Associated (Cas) Genes Sales Forecast (2021-2026)12.2.2 North America: CRISPR And CRISPR-Associated (Cas) Genes Revenue Forecast (2021-2026)12.2.3 North America: CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast by Country (2021-2026)12.3 Europe CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast (2021-2026)12.3.1 Europe: CRISPR And CRISPR-Associated (Cas) Genes Sales Forecast (2021-2026)12.3.2 Europe: CRISPR And CRISPR-Associated (Cas) Genes Revenue Forecast (2021-2026)12.3.3 Europe: CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast by Country (2021-2026)12.4 Asia Pacific CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast (2021-2026)12.4.1 Asia Pacific: CRISPR And CRISPR-Associated (Cas) Genes Sales Forecast (2021-2026)12.4.2 Asia Pacific: CRISPR And CRISPR-Associated (Cas) Genes Revenue Forecast (2021-2026)12.4.3 Asia Pacific: CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast by Region (2021-2026)12.5 Latin America CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast (2021-2026)12.5.1 Latin America: CRISPR And CRISPR-Associated (Cas) Genes Sales Forecast (2021-2026)12.5.2 Latin America: CRISPR And CRISPR-Associated (Cas) Genes Revenue Forecast (2021-2026)12.5.3 Latin America: CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast by Country (2021-2026)12.6 Middle East and Africa CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast (2021-2026)12.6.1 Middle East and Africa: CRISPR And CRISPR-Associated (Cas) Genes Sales Forecast (2021-2026)12.6.2 Middle East and Africa: CRISPR And CRISPR-Associated (Cas) Genes Revenue Forecast (2021-2026)12.6.3 Middle East and Africa: CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast by Country (2021-2026) 13 Market Opportunities, Challenges, Risks and Influences Factors Analysis13.1 Market Opportunities and Drivers13.2 Market Challenges13.3 Market Risks/Restraints13.4 Porters Five Forces Analysis13.5 Primary Interviews with Key CRISPR And CRISPR-Associated (Cas) Genes Players (Opinion Leaders) 14 Value Chain and Sales Channels Analysis14.1 Value Chain Analysis14.2 CRISPR And CRISPR-Associated (Cas) Genes Customers14.3 Sales Channels Analysis14.3.1 Sales Channels14.3.2 Distributors 15 Research Findings and Conclusion 16 Appendix16.1 Research Methodology16.1.1 Methodology/Research Approach16.1.2 Data Source16.2 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from the huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become a brand of quality assurance in the consulting industry.

See more here:
CRISPR And CRISPR-Associated (Cas) Genes Market which company is the market leader and how much its sales in 2020 and what it's expected sales for the...

Scientists at the Council of Scientific & Industrial Research-Institute of Genomics and Integrative Biology have come up with a low-cost coronavirus test that will not require any expensive machines for detection of the pathogen.

The test can detect the coronavirus disease (Covid-19) within one hour and is expected to be available for the first phase of testing in four weeks.

Named after ''Feluda'', the detective character in legendary filmmaker Satyajit Ray's stories, although it is also an acronym for FNCAS9 Editor-Linked Uniform Detection Assay.

The test uses CRISPR gene-editing technology to identify and target the genetic material of Sars-CoV2, the virus that causes Covid-19. The test has been developed by Debojyoti Chakraborty and Souvik Maiti as a simpler way of detecting SARS-coV2 presence in clinical samples.

The CRISPR-based Feluda testing works by combining CRISPR biology and paper strip chemistry. Briefly, Cas9 protein, a component of the CRISPR system, is barcoded to interact specifically with the Sars-CoV2 sequence in the patients genetic material.

The complex of Cas9 with Sars-CoV2 is then applied to a paper strip, where using two lines (one control, one test) make it possible to determine if the test sample was infected with Covid-19.

Using the innovative chemistry on a paper strip, the CRISPR complex, bound to that specific sequence, can be visualised as a positive band, like one sees in simple pregnancy tests. The entire diagnostic process takes about one hour, starting from RNA to giving a visual readout on the strip.

Most labs are working with PCR(polymerase chain reaction)-based technology, which is costly and needs a lab set-up. The paper strip does not require (biosafety) Level-2 or Level-3 lab for testing and can be done in any path lab.

Unlike other CRISPRtests that use CAS12 and CAS13 proteins to detect Sars-CoV2, the CSIR-IGIB kit technology uses CAS9 protein (CRISPR-associated protein 9) to identify and bind to the target sequence.

CRISPR, which is short for Clustered Regularly Interspaced Short Palindromic Repeats, is a gene-editing technology that can be used to detect a specific snippet of DNA from a sequence. It can also be used to turn genes on or off without altering their sequence.

Feluda is not limited to Covid-19. The team has been working on Feluda for the past two years to develop an assay that can work on detecting any DNA-RNA or their mutations.

This is the only Covid-19 testing kit that has been developed using CRISPR-based technology in India. Feluda has been licenced to Tata Sons, which will commercialise the technology for Covid-19 detection.

Each Feluda test costs Rs 500 in the lab, and is expected to bring the cost of testing down from the Rs 4,500 per test for the real-time polymerase chain reaction test (RT-PCR), which is the only available test for detecting current Covid-19 infection.

Follow this link:
This Test Named After Satyajit Ray's Detective Character Can Reportedly Detect The Virus In An Hour - ScoopWhoop

Covid-19 has changed life as we know it. It has also accelerated already rapid trends in innovation and collaboration across the scientific community.

As the pandemic spreads across the globe, researchers are racing to develop diagnostics, vaccines and treatments. In the pursuit of new solutions to tackle SARS-CoV-2, the novel coronavirus that causes Covid-19, researchers have been turning to machine learning, AI and high-throughput experimental automation that aid in development. Another powerful tool they are using to accelerate the process is CRISPR. This gene-targeting and gene-editing technology, based on the mechanism that bacteria naturally use to fight viruses, is already proving useful in our joint fight against this new virus.

CRISPR Advances Covid-19 TestingWe know early detection of SARS-CoV-2 is essential to isolating infected patients and managing appropriate healthcare responses. Recently, researchers at MIT published a rapid CRISPR-Cas13-based COVID-19 detection assay protocol.Since CRISPR can be modified to target nearly any genetic sequence, it can be used to detect SARS-CoV-2 RNA in a patient sample. This assay utilizes an RNA-targeting CRISPR nuclease to help scientists detect the SARS-CoV-2 RNA from patient samples within 60 minutes. More recently, an improved assay was developed by researchers at MIT that was shown to provide faster and more robust results.

Utilizing another CRISPR nuclease that is thermostable, they developed a test that in one step copies the viral RNA in a patient sample, such as saliva, into the more stable DNA and then specifically identifies a SARS-CoV-2 gene sequence. Performing this point-of-care assay requires minimal lab equipment and resources, as it only needs a few reagents and a heat source, delivering results in as little as 40 minutes. Supplementing existing tests with new CRISPR-based approaches can broaden accessibility to Covid-19 testing, a key strategy for stopping the spread through track and trace efforts, as outlined by the World Health Organization.

CRISPR Helps Engineer Future TreatmentsPreviously, the genome-engineering power of CRISPR has been directed at fighting genetic diseases. But more recently, its also being harnessed to fight infectious diseases, now including the new coronavirus.

Understanding how a pathogenic disease operates at the host-pathogen interface is critical to developing new treatments. CRISPR-based genome engineering enables researchers to study how SARS-CoV-2 interacts with human cells and generate the appropriate cell models that could lead to faster discovery of a potential new treatment or an existing drug combination that may provide a treatment solution. Once a potential treatment is identified, CRISPR makes the next step drug target screening more efficient, advancing us more quickly to a viable treatment option.

As an example of this approach in action, researchers are exploring if CRISPR can be used to verify the functional relevance of human genes recently identified to interact with SARS-CoV-2 proteins. The investigation of the molecular mechanisms of the novel virus can ultimately help identify drug combinations that have the best potential to treat those infected.

Current Fight for the Future of Human HealthGenome engineering has been rapidly harnessed by academic and non-profit institutions, the biopharma industry, and scientific pioneers to develop Covid-19 testing and treatment solutions. CRISPR-based genome engineering enables researchers to study how SARS-CoV-2 interacts with human cells and generate the appropriate cell models that could lead to faster discovery of a potential new treatment or an existing drug combination that may provide a treatment solution.

Beyond this, the unprecedented innovation taking place in response to the Covid-19 pandemic will provide a foundation for improving human health in the future. Additionally, as technologies and understanding mature, new approaches, such as engineered cell therapies, will become part of the toolkit in future responses to global health challenges.

The current scientific response is representative of the future of life sciences a future where we integrate multiple technologies and disciplines including high throughput experimental automation, machine learning and agile, programmable tools such as CRISPR to fundamentally change our approach to research and development. We are seeing a new bar being set on the speed of science as the research community comes together, leveraging these technologies to respond to the Covid-19 pandemic at unprecedented velocity. Once the public health crisis subsides and the research halted by the pandemic resumes, the need for these transformative tools, technologies and approaches to life science research and development will be greater than ever.

Photo: wildpixel, Getty Images

Excerpt from:
How CRISPR can help us win the fight against the pandemic - MedCity News

CRISPR-Cas9 gene-editing is one of the most powerful tools available to modern science, but genetically-modified organisms (GMOs) in food are subject to some tight regulations. Now, researchers at North Carolina State University have created a new version of CRISPR that lets scientists edit crops without introducing new DNA, meaning they technically arent GMOs.

CRISPR-Cas9 allows for precise cut-n-paste edits to DNA in living cells. An RNA guide sequence directs the system to the target section of the genome. Once there, an enzyme, usually Cas9, snips out the sequence then deletes it or replaces it with something else. In this way, scientists can cut out problem genes, such as those that cause disease, or add new beneficial ones, such as giving crops better pest resistance.

For the new study, the researchers tweaked the process to make a cleaner edit in plants. It uses a process known as lipofection, where positively-charged lipids are used to build a kind of bubble around the Cas9 and RNA mechanisms. When injected into the organism, this bubble binds to and fuses with the cellular membrane, which pushes the CRISPR system into the cell itself. The method also uses a Cas9 protein itself, rather than the Cas9 DNA sequence.

The team tested the method by introducing fluorescent proteins into tobacco plants. And sure enough, after 48 hours the edited plants were glowing, indicating it had worked.

Wusheng Liu/NC State University

The new method has a few advantages over existing ones, the team says. Its easier to target the desired genetic sequence, and opens up new crops that couldnt be edited with existing methods. Plus, the protein only lasts for a few days before degrading, which reduces off-target edits.

But the most important advantage is that the resulting crops arent considered GMOs. Since the new method doesnt use Cas9 DNA, it doesnt introduce foreign DNA into the plant, which is an important distinction.

This was the first time anyone has come up with a method to deliver the Cas9 protein through lipofection into plant cells, says Wusheng Liu, lead author of the study. Our major achievement was to make that happen. Also, since many consumers prefer non-GMO specialty crops, this method delivers the Cas9 protein in a non-GMO manner.

As useful as genetic engineering can be, the term GMO has negative connotations for many people, who believe there are health concerns with eating these crops or meats. Other problems include the chance of modified plants or animals escaping into the wild, where they can spread their new genes to the native population, affecting ecosystems.

As such, the US Department of Agriculture (USDA) and the Food and Drug Administration (FDA) have regulations on which edited crops and animals are allowed in food. And theyve decided that the line is drawn at introducing foreign genes into an organism.

It makes sense. Humans have been genetically-engineering plants and animals for millennia, through selective breeding. Many of our most widely-eaten crops are bigger, tastier, and easier to eat or grow, to the point that they hardly resemble their wild counterparts anymore.

CRISPR and other gene-editing tools can be the next generation of this process. By removing problematic genes or ensuring that specific ones are turned on or off, scientists arent really creating anything new. Some individuals naturally have mutations that do the same thing all the scientists are really doing is removing the element of chance, genetically.

In 2015, a new type of salmon became the first genetically engineered animal approved by the FDA for human consumption. In 2016, a Swedish scientist grew, harvested and served up CRISPR cabbage after approval by the Swedish Board of Agriculture. In both cases, the products were allowed because they were functionally identical to wild-type organisms the scientists had just chosen beneficial genes from an existing natural pool, without introducing foreign DNA.

That said, the rules aren't the same everywhere. In 2018 the Court of Justice of the European Union somewhat controversially ruled that tough GMO laws applied to crops that had been edited even if new DNA hadn't been inserted. The issue will likely remain fragmented, but for the NC State team at least, their crops aren't GMOs according to their own country's regulations.

However, there are still some hurdles to overcome before the new method becomes viable. The team says that lipofection can only be done if the outer wall of the plant cell is removed first. This kind of plant cell, known as a protoplast, allows scientists to more easily tweak the genes, but it isnt possible in all types of crops, and even when it does work, its a complex process.

Instead, the researchers are exploring other options that dont require removing the cell wall at all. One such alternative is to use CRISPR to introduce the Cas9 protein into pollen grains, which can then go on to fertilize another plant. Some of the offspring will have the required genetic edits from day one.

The researchers plan to investigate this latter method in tomatoes and hemp first, before moving onto others.

The new study was published in the journal Plant Cell Reports.

Source: NC State University

Read the original:
New CRISPR method edits crops without technically making them GMOs - New Atlas